



**HAL**  
open science

# Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis

Octave Guinebretiere, Thomas Nedelec, Laurène Gantzer, Beranger Lekens, Stanley Durrleman, Céline Louapre

► **To cite this version:**

Octave Guinebretiere, Thomas Nedelec, Laurène Gantzer, Beranger Lekens, Stanley Durrleman, et al.. Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis. *Neurology*, 2023, 101 (24), 10.1212/WNL.0000000000207981 . hal-04330030

**HAL Id: hal-04330030**

<https://hal.science/hal-04330030v1>

Submitted on 8 Dec 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1     **Association Between Diseases and Symptoms Diagnosed in Primary Care**  
2                     **and the Subsequent Specific Risk of Multiple Sclerosis**

3  
4     **Octave Guinebretière, MSc<sup>1</sup>; Thomas Nedelec, PhD<sup>1</sup>; Laurène Gantzer, MSc<sup>2</sup>; Beranger**  
5     **Lekens, MSc<sup>2</sup>; Stanley Durrleman, PhD<sup>1</sup>; Céline Louapre, MD, PhD<sup>1,3</sup>**

6  
7     Affiliation

- 8         1. Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France  
9         2. Cegecim R&D, Boulogne-Billancourt, France  
10        3. Department of Neurology, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Assistance  
11        Publique-Hôpitaux de Paris, Paris, France

12  
13     **Number of words (body of the manuscript): 4499**

14  
15     Corresponding author

16  
17     Celine Louapre

18     Paris Brain Institute (ICM),

19     Hôpital Pitié-Salpêtrière,

20     47 bd de l'Hôpital,

21     75651 Paris Cedex 13

22     France

23     E-mail: [celine.louapre@aphp.fr](mailto:celine.louapre@aphp.fr)

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Objective:**

51 Previous studies have reported a possible prodrome in multiple sclerosis (MS) defined by non-  
52 specific symptoms including mood disorder or genito-urinary symptoms and increased health  
53 care use detected several years before diagnosis.

54 This study aimed to evaluate agnostically the associations between diseases and symptoms  
55 diagnosed in primary care and the risk of multiple sclerosis (MS) relative to controls and two  
56 other autoimmune inflammatory diseases with similar population characteristics, namely lupus  
57 and Crohn's disease.

### 58 **Methods:**

59 A case-control study was conducted using electronic health records from the Health  
60 Improvement Network database in the UK and France. We agnostically assessed the  
61 associations between 113 diseases and symptoms in the five years before and after diagnosis in  
62 patients with subsequent diagnosis of MS. Individuals with a diagnosis of MS were compared  
63 to individuals without MS, and individuals with two other auto-immune diseases, Crohn's  
64 disease and lupus.

### 65 **Results:**

66 The study population consisted of patients with MS (n= 20,174), patients without MS  
67 (n=54,790), patients with Crohn's disease (n=30,477) or patients with lupus (n=7,337). Twelve  
68 ICD-10 codes were significantly positively associated with the risk of MS compared to controls  
69 without MS. After considering ICD-10 codes suggestive of neurological symptoms as the first  
70 diagnosis of MS, five ICD-10 codes remained significantly associated with MS: depression  
71 (UK OR 1.22 [95%CI 1.11-1.34]), sexual dysfunction (1.47 [1.11-1.95]), constipation (1.5  
72 [1.27-1.78]), cystitis (1.21 [1.05-1.39]), and urinary tract infections of unspecified site (1.38  
73 [1.18-1.61]). However, none of these conditions was selectively associated with MS in  
74 comparisons with both lupus and Crohn's disease. All five ICD-10 codes identified were still  
75 associated with MS during the five years after diagnosis.

76 **Conclusion:**

77 We identified 5 health conditions associated with subsequent MS diagnosis, which may be  
78 considered not only prodromal but also early-stage symptoms. However, these health  
79 conditions overlap with prodrome of two other autoimmune diseases, hence lacking specificity  
80 to MS.

81

82 **Introduction**

83

84 A mismatch between clinical symptoms and visible brain lesions on magnetic resonance  
85 imaging (MRI), the so-called clinico-radiological paradox, has been known for decades in  
86 multiple sclerosis (MS).<sup>1</sup> While this phenomenon has been linked to the heterogeneity of MS  
87 clinical outcomes, it could also explain why certain subtle, non-specific symptoms were  
88 identified prior to the neurological diagnosis and described as MS prodrome. Moreover, recent  
89 studies suggest that patients with MS display increased serum neurofilament biomarkers before  
90 the onset of typical MS symptoms.<sup>2,3</sup> Prodromal health conditions would not be sufficiently  
91 pronounced to warrant diagnosis, but they might indicate the start of the neuroinflammatory  
92 process, similar to preclinical pathophysiological mechanisms occurring before clinical onset  
93 in other neurological diseases.<sup>4,5</sup> The recognition of a prodromal period would help to gain  
94 knowledge on the consequences of the appearance and accumulation of MS lesions but also on  
95 the temporality of MS pathophysiological processes. Although it is unlikely that the description  
96 of a prodrome in MS might lead to specific intervention in the general population, it could be  
97 important to identify such period in populations with a high risk of developing MS due to  
98 familial history or in the case of radiologically isolated syndrome (RIS). A recent study from  
99 the RISC consortium has found a 51% cumulative probability of a first clinical event at 10 years  
100 in patients with RIS.<sup>6</sup> For those at highest risk of a first clinical event, identifying prodromal

101 health conditions within these 10 years might lead to potential earlier therapeutic intervention.  
102 This assumption would be relevant only if MS prodrome would be rather specific to MS, and  
103 not similar to other auto-immune conditions.

104 Previous studies have reported pre-diagnostic features, such as depression, fatigue, sleep  
105 disorders or urinary infections, associated with MS and occurring up to 10 years before  
106 diagnosis.<sup>7-9</sup> However, most studies on MS prodrome have focused on either hypothesis-driven  
107 searches for non-specific symptoms,<sup>8,9</sup> or major disease categories.<sup>7</sup> It is also important to  
108 compare the early presentation of MS with other inflammatory diseases and to determine which  
109 of the pre-diagnosis features are specific to MS. There is also a need for further analyses of  
110 differences in the clinical presentation of MS prodrome by age,<sup>10</sup> sex,<sup>9-11</sup> and year of diagnosis<sup>12</sup>  
111 in order to improve our understanding of the prodrome onset.

112 We set up and analyzed two nested case-control studies based on data from two large primary  
113 care databases in the UK and France, extracted from The Health Improvement Network (THIN)  
114 database. We sought to confirm the previously reported associations<sup>7-9</sup> between pre-diagnosis  
115 features and the subsequent diagnosis of MS, to assess whether combining these pre-diagnosis  
116 features could provide a greater ability to discriminate between patients with subsequent MS  
117 and patients without MS, and to compare presentations before and after diagnosis. We also  
118 aimed to compare MS cohort with control cohorts of patients with other autoimmune diseases  
119 — lupus and Crohn's disease — to determine whether the features identified were specific to  
120 MS or common to several autoimmune diseases. Lupus and Crohn's disease were selected  
121 because both have female predominance, affect young adults,<sup>13</sup> and both present pre-clinical  
122 non-specific signs and symptoms. In lupus, increased pre-diagnosis healthcare use has been  
123 reported,<sup>14</sup> notably childhood-onset lupus cases had higher frequency of pre-diagnosis  
124 psychiatric conditions compared to matched controls.<sup>15</sup> In Crohn's disease, an association  
125 between pre-diagnosis depression and incident Crohn's disease was reported.<sup>16</sup> Although these

126 diseases have distinct phenotypes and involve different target organs, there is an overlap of  
127 environmental risk factors for disease occurrence or exacerbation such as stress and smoking.<sup>17-</sup>  
128 <sup>20</sup> Hence, to determine which health conditions are specific to MS prodrome, we compared MS  
129 to both a systemic (lupus) and an organ-specific (Crohn's disease) auto-immune disease.

130

## 131 **Methods**

### 132 *Study design and participants*

133 We used The Health Improvement Network (THIN) database,<sup>21</sup> a large standardized European  
134 database of fully anonymized and non-extrapolated electronic medical records collected from  
135 physicians by the company GERS SAS<sup>21</sup> and coded according to the International Classification  
136 of Diseases, 10th revision (ICD10). The THIN database complies with all current European  
137 data protection laws (General Data Protection Regulation) and adheres to the Observational  
138 Medical Outcomes Partnership model.<sup>21</sup> Details on data collection are specified in the method  
139 section of supplementary materials. We considered data recorded from Jan 1, 1996, to March  
140 28, 2022 in the UK and from Jan 1, 1998, to March 28, 2022 in France.

141 In both countries, we defined a cohort of cases with incident MS and respectively three other  
142 control cohorts: i) individuals without incident MS; ii) patients with incident lupus; iii) patients  
143 with incident Crohn's disease. Patients with MS were required to have a record of the ICD-10  
144 code G35, lupus the ICD-10 code M32, and Crohn's disease the ICD-10 code K50. The amount  
145 of co-occurrence between these diseases in our database did not warrant the exclusion of  
146 individuals with more than one auto-immune disease. We first compared the MS cohort to  
147 controls without MS in primary and sensitivity analyses and used all significant findings for  
148 further analyses in which we compared the MS cohort to lupus and Crohn's disease cohorts. In  
149 the primary analysis, index date was defined as the earliest date of at least one of the following  
150 conditions: i) G35 code; ii) other ICD-10 codes related to a demyelinating event (e.g myelitis

151 or optic neuritis, complete list in **eTable 1**). Age at MS onset was defined as age at the index  
152 date. As exact diagnosis date may be difficult to firmly determine in primary care setting, we  
153 also ran a sensitivity analysis, in which we shifted the index date further back, to the earliest  
154 ICD-10 code indicating neurological symptoms (e.g. paresthesia, dizziness) which could be  
155 interpreted retrospectively as MS clinical onset.<sup>12</sup> For this purpose, we used the ICD-10 codes  
156 listed in **eTable 2**.

157

158 For each country, we randomly selected three controls without MS for each MS case, matched  
159 in terms of age at index date, sex and year at index date. A symptom was considered to be  
160 present if either the corresponding ICD-10 code or the prescription of a symptom-specific drug  
161 was recorded (**eTable 3** and **eTable 4**). Only individuals with available data at least two years  
162 before the index date in the case and control cohorts were included, as shown in the flowchart  
163 in **eFigure 1, 2**. For the sensitivity analysis, we applied the same shift in index date to each  
164 matched control. We also defined a cohort of patients with MS and individuals without MS  
165 with at least 5 years of data before diagnosis to ensure balanced available data between the two  
166 groups.

167

#### 168 *Exposure extraction on the basis of ICD10 classification*

169 We defined past exposure to the health conditions considered, based on the ICD-10 codes  
170 provided directly in both the French and UK databases. The validity of significant diagnoses in  
171 THIN is high.<sup>22-24</sup> More specifically for MS, a previous study using one ICD-10 code G35 to  
172 define MS reported similar incidence and prevalence findings to a General Practice Research  
173 (GPRD) study.<sup>25,26</sup> This previous study also had similar results to an internal validation study  
174 of MS identification in the GPRD which reported high accuracy.<sup>26,27</sup> We used the first three  
175 characters of the code, defining disease category. In this exploratory approach, we assessed the



176 association between MS and each of the health conditions defined by ICD-10 codes with a  
177 relative frequency of more than 0.5% in both MS and control cohorts and in both countries.

178

### 179 *Standard protocol approvals, registrations, and patients consent*

180 Approval was sorted before carrying out this study (and for the use of datasets). The study was  
181 a retrospective analysis of secondary anonymised patient data only. For the UK database, data  
182 is only available to researchers carrying out approved medical research. Ethical approval was  
183 granted by the NHS South-East Multicentre Research Ethics Committee in 2003 (ref:  
184 03/01/073) for establishment of the THIN database, and it was updated in 2011. A further  
185 update and approval was granted in 2020 by the NHS South Central, Oxford C Research Ethics  
186 Committee (Ref: 20/SC/0011). For the French Database, several audits were conducted by  
187 CNIL (Commission Nationale de l'Informatique et des Libertés, the French authority  
188 responsible for the protection of personal data). Data are available from the GERS SAS for  
189 researchers who meet the criteria for access to confidential data. Researchers willing to replicate  
190 the results should address a request to the Cegedim company (info@the-health-improvement-  
191 network.co.uk). The study was approved by the THIN Scientific Research Committee (SRC)  
192 on 4th Feb 2022 (SRC reference 21-016). There was no need for written informed consent from  
193 participants. No photographs, videos, or other information of recognizable persons is used in  
194 this article. Authorization for disclosure was therefore not necessary.

195

### 196 **Statistical analysis**

197 We used logistic regression to analyse the association between each health condition  
198 corresponding to a specific ICD10 code and the diagnosis of MS. We quantified the association  
199 by calculating odds ratios (ORs) and 95% CIs for exposure to a particular health condition  
200 within five years of the index date. *P* values were corrected for multiple comparisons with the

201 Bonferroni method, with an alpha risk of 5%. Values of  $p < 0.0004$  in two-tailed tests were  
202 considered significant ( $p = 0.05$  with Bonferroni correction for 113 potential exposures). As the  
203 exclusion of some patients with MS and controls without MS (**eFigure 1** and **eFigure 2**) led to  
204 a break in the matching, all analyses were adjusted for sex (dichotomous variable), age at  
205 diagnosis (continuous variable), year at diagnosis (continuous variable), and the duration of  
206 follow-up (continuous variable). For the comparison between MS and other autoimmune  
207 diseases, we performed a logistic regression analysis controlled for age at index date, sex, and  
208 duration of follow-up.

209 We studied post-diagnosis presentation, using a Cox regression model with MS as the exposure  
210 of interest, considering the given health condition as the outcome and the time to the event or  
211 the time to last visit or data extraction as the time variable. To compare pre and post-diagnosis  
212 presentation, we restricted the cohorts of patients with incident MS and no MS to patients with  
213 at least two years of data before and after the index date.

214 We stratified our analyses before and after MS diagnosis on sex, age at diagnosis, and year at  
215 diagnosis. To stratify on age at diagnosis, we split the data into three cohorts of equal size, using  
216 the 33<sup>rd</sup> and 66<sup>th</sup> percentiles for age at diagnosis as cutoff points. To stratify on year at diagnosis,  
217 we used the year 2010 and 2017 since new MS diagnostic criteria were defined in 2010<sup>28</sup> and  
218 2017.<sup>29</sup> These criteria have been shown to facilitate earlier diagnosis and to increase sensitivity  
219 of MS diagnosis.<sup>30,31</sup>

220 In investigations of temporal associations, we also used the significant findings from the  
221 comparison of the MS cohort to individuals without MS, with the exception of one condition,  
222 to chart the single-year prevalence of the prescription of symptom-specific drugs for each of  
223 the 15 years before and after MS diagnosis. We also investigated healthcare use, based on the  
224 mean number of GP visits per year. To handle patients who were not followed during the entire  
225 30 years period, the prevalence was computed based on the exact number of patients at risk for

226 each specific year. We also included analyses on specific subsets of patients who were followed  
227 for at least x number of years (where x can be 15, 10, or 5) before and after diagnosis.  
228 Finally, we conducted the analyses in each country, and we also pooled the data by combining  
229 individual patient records from the two countries, adding country as covariate to account for  
230 heterogeneity between countries (referred as pooled analyses). Indeed, data homogeneity is  
231 partly guaranteed by shared data collection process and OMOP data format between countries,  
232 but heterogeneity remains in the type of population and healthcare settings in each country.  
233 Pooling individual patient records allowed to increase statistical power, and presenting results  
234 in separate countries allowed to examine the consistency of findings in different settings.

235

## 236 **Results**

### 237 *Demographic information*

238 In this analysis, from French and British health records, we included respectively 4,366 and  
239 15,808 patients with MS, 12,531 and 42,226 individuals without a diagnosis of MS, 2,041 and  
240 5,296 patients diagnosed with lupus, and 9,605 and 20,872 patients diagnosed with Crohn's  
241 disease. Age and sex distribution of MS cohort, and the three control cohorts of patients with  
242 other autoimmune diseases or individuals without MS are presented in **Table 1**.

243 Median age at MS diagnosis was 46 years (37–57 years) in the UK and 44 years (34–54 years)  
244 in France, with an age at first MS symptoms of 44 years (34–54 years) in the UK and 42 years  
245 (32–52 years) in France. For patients diagnosed after 2017, age at first MS symptoms decreased  
246 to 39 years (30–50 years) in the UK and 40 years (30–51 years) in France. More follow-up data  
247 were available from the UK sample, with 9 person-years of data available before the index date  
248 in the full analytical cohort versus only 6 person-years on average for the French sample.  
249 Median number of visits per year was also higher in the UK than in France.

250 Female predominance was observed in MS, lupus, and Crohn's disease cohorts.

251 Lupus cohort contained slightly older patients and included more women than MS cohort,  
252 whereas Crohn's disease cohort contained younger patients, with fewer women than MS cohort.  
253 Co-occurrence between MS and lupus and MS and Crohn's disease was respectively 6 (0.13%)  
254 and 15 (0.34%) in France and 89 (0.56%) and 28 (0.18%) in the UK, which did not warrant  
255 further consideration.

256

### 257 *Primary analysis*

258 Overall, 113 health conditions were considered in the French and UK databases (**eTable 5**). We  
259 identified 12 health conditions as significantly positively associated with a diagnosis of MS  
260 when recorded in the five years before MS diagnosis, in both countries (**eTable 6**). Only one of  
261 these conditions was a neurologic disorder: epilepsy and recurrent seizures. Two psychiatric  
262 disorders, depression and sexual dysfunction (not caused by organic disorder or disease) were  
263 more frequently recorded in patients with MS than in controls without MS. The other associated  
264 health conditions were related to disorders of the vestibular system, functional intestinal  
265 disorders (principally constipation), limb pain, cystitis, disorders of the urinary system  
266 (principally urinary tract infection), skin paresthesia, dizziness and giddiness, headache, and  
267 malaise and fatigue. Skin paresthesia, dizziness and giddiness, and disorders of vestibular  
268 function may be interpreted as MS symptoms that were not recognized as such by the GP.

269

### 270 *Sensitivity analysis*

271 Only major depressive disorder, sexual dysfunction, constipation, cystitis, and urinary tract  
272 infection of unspecified site remained significantly more frequent in patients with MS than in  
273 controls without MS in the sensitivity analysis (**Figure 1, eTable 6**). Overall, 91.2% of the  
274 patients diagnosed with functional intestinal disorders (ICD-10 code K59) in the UK and 92.4%  
275 of those diagnosed with such disorders in France had constipation (ICD-10 code K59.0).

276 Similarly, 98.8% of the patients diagnosed with disorders of the urinary system (ICD-10 code  
277 N39) in the UK and 97.9% of those diagnosed with such disorders in France had urinary tract  
278 of unspecified site infection (ICD-10 code N39.0). In the following, the ICD-10 codes K59 and  
279 N39 will be regarded respectively as constipation and urinary tract infection of unspecified site.  
280 When restricting the analysis to patients with at least five years of history before the index date,  
281 all health conditions remained significantly positively associated in the UK and in the pooled  
282 analysis; however, sexual dysfunction, cystitis, and urinary tract infection (site not specified)  
283 were not significantly associated in the French cohort, most likely due to a lack of statistical  
284 power (**eTable 7**). Summary statistics for this cohort are presented (**eTable 8**). Characteristics  
285 of the cohorts are similar to those of the original cohorts with at least two years of retrospective  
286 data.

287

#### 288 *Pre and post-diagnosis analysis*

289 To facilitate the pre and post diagnosis comparison, we restricted our cohorts to patients with  
290 at least two years of data before and after diagnosis. Characteristics of the cohorts are similar  
291 to those of the original cohorts with at least two years of retrospective data (**eTable 9**). All  
292 health conditions considered to be associated with MS diagnosis in the pre-diagnosis analysis  
293 were also associated with MS diagnosis in the post-diagnosis analysis in both France and UK  
294 cohorts (**Table 2** in pooled analysis, and **eTable 10 and 11** for UK and France respectively).  
295 Moreover, in the UK and in the pooled analysis (**Table 2** and **eTable 10**), ORs for all conditions  
296 were significantly higher in the post-diagnosis period compared to the pre-diagnosis period.

297

#### 298 *Combination of pre-diagnosis health conditions*

299 Combining observed pre-diagnosis features significantly increased the ability to discriminate  
300 MS cases and controls without MS for men (pooled OR 2.46, 2.05–2.95 for at least two

301 features), whereas no effect was observed for women or in subgroups stratified by age at onset  
302 (**Table 3**).

303

#### 304 *Comparison with other autoimmune diseases*

305 Depression, sexual dysfunction, cystitis and urinary tract infection (site not specified) were  
306 found to be more frequent among people subsequently diagnosed with MS than in Crohn's  
307 disease patients, in the pooled analysis of data from France and the UK (**Figure 2** in pooled  
308 analysis, and **eFigure 3** for UK and France). However, no health condition was found to be  
309 significantly associated with MS in comparisons with lupus patients. Constipation was found  
310 to be significantly positively associated with Crohn's disease in comparison to MS.

311

#### 312 *Longitudinal analysis*

313 We found that the difference in the prevalence of antidepressant use between MS and controls  
314 without MS was much more pronounced after than before MS diagnosis. Indeed, the period  
315 prevalence increased from 14% and 10% for MS patients and controls without MS,  
316 respectively, in the five years before diagnosis to 37% and 19%, respectively, in the five years  
317 after MS diagnosis, with the number of MS patients using antidepressants increasing by 20%  
318 during the year of MS diagnosis (**Figure 3** for the pooled analysis, **eFigure 4** and **eFigure 5** for  
319 the UK and French cohort respectively). Increase in antidepressant prescriptions was less  
320 pronounced at the time of diagnosis for patients with lupus or Crohn's disease. For MS, lupus  
321 and Crohn's disease, there was a rise of number of GP visits after the diagnosis, with a peak  
322 with the first two years post-diagnosis of these auto-immune conditions. Concordant temporal  
323 trends of prescriptions and GP visits were observed in cohorts with data in the entire time  
324 periods (**eFigure 6** and **eFigure 7**).

325

326 *Stratification by age at diagnosis, sex, and year of diagnosis*

327 The ORs for pre-diagnosis autonomic symptoms (functional intestinal disorders, cystitis, and  
328 urinary tract infection of unspecified site) increased with increasing age at diagnosis, though  
329 not reaching significance, whereas those for depression and sexual dysfunction did not vary  
330 with age. Overall, ORs for pre-diagnosis presentations were higher in men than women,  
331 especially for urinary tract infection (women: OR 1.29, 1.12–1.48; men: OR 2.16, 1.50–3.10).  
332 Finally, pre-diagnosis depression and constipation decreased with more recent year of  
333 diagnosis, though not reaching significance (**Table 2**).

334

335

## 336 **Discussion**

337

338 We used two large independent primary care databases to explore pre-diagnosis health  
339 conditions associated with MS. To our knowledge, this is the first transnational data-driven  
340 study of the pre and post-diagnosis presentations of MS.

341 Median age at first diagnosis was 39 and 40 in the UK and France in the sensitivity analysis  
342 after 2017. This is slightly higher than the reported mean age at diagnosis of 37.6 years in a  
343 previous study<sup>12</sup>, but considerably lower than the reported 43 years and 47 years in other  
344 previous studies.<sup>32,33</sup> These previous studies were based on administrative claims data. In a  
345 smaller clinical cohort linked to administrative data, mean age at symptom onset (as recalled  
346 by the patient during a neurologist visit) was 36.5 years suggesting that the first clinical  
347 manifestations of the disease might not have been recorded in our study and other previous  
348 studies.<sup>32</sup>

349 In the primary analysis, we identified a group of symptoms recorded by GPs during the five-  
350 year period leading up to MS diagnosis. However, some of these symptoms suggested that the

351 patient had already experienced a relapse or onset of MS and, therefore, that the diagnosis of  
352 MS recorded in the database was later than the actual onset of MS.<sup>12</sup> In the sensitivity analysis  
353 using the earliest symptom suggestive of MS as the index date, five conditions were  
354 significantly associated with a subsequent diagnosis of MS and were considered putative pre-  
355 diagnosis features. Our findings confirmed the reported pre-diagnosis associations for  
356 autonomic symptoms (intestinal function disorders, cystitis, and urinary tract infections)<sup>8,9,32,34</sup>  
357 and depression.<sup>7,8,32,34</sup> Symptoms of sexual dysfunction have been recognized to occur at or  
358 after the onset of MS symptoms or MS diagnosis;<sup>35-37</sup> however, to our knowledge, no other  
359 study has ever reported a health condition related to sexual dysfunction as a pre-diagnosis  
360 feature of MS. Sexual dysfunctions reported were coded as a psychological disorder not caused  
361 by a disease. It remains unclear whether this health condition results from the patient's  
362 experience of the prodrome — in which case, the psychological nature of the sexual dysfunction  
363 would be confirmed — or whether it is caused by an ongoing disease, such as medullary MS  
364 lesions, if the patient reports no motor or sensory symptoms. Other health conditions identified  
365 in prodrome studies in the primary care context, such as anxiety, fatigue, anemia, and sleep  
366 disorders,<sup>8,34,38</sup> were not significantly associated with MS diagnosis in our sensitivity study.  
367 This study is original as it investigates the possibility of an MS prodrome in two large countries,  
368 and it may have eliminated several spurious correlations.

369 In our study, ORs for depression were higher in France compared to the UK, this difference  
370 could be attributed to the difference in healthcare system or difference in the type of  
371 remuneration (capitation based for the UK versus fee-for-service based for France).

372 A previous study reported a positive association between pre-diagnosis depression and the  
373 incidence of inflammatory bowel disease, MS, and rheumatoid arthritis separately, which could  
374 suggest similarities in the pre-diagnosis presentations (potentially due to shared risk factors or  
375 etiology) of auto-immune diseases.<sup>39</sup> In our study, none of the observed associations was



376 selectively associated with MS in comparison with lupus, whereas urinary tract infection,  
377 cystitis, sexual dysfunction, and major depressive disorder were found to be selectively  
378 associated with MS in a comparison with Crohn's disease. However, these associations were  
379 weak, suggesting that urinary tract infections, sexual dysfunction, and major depressive  
380 disorder may not be specific to MS. The finding that depression is specifically associated with  
381 MS in comparison to Crohn's disease contradicts a previous study which found no association.<sup>12</sup>  
382 The other observed conditions were not tested in other studies. A previous review reported that  
383 studies of the preclinical phase of lupus are complicated by the fact that lupus cannot be  
384 diagnosed until sufficient clinical manifestations have occurred, potentially accounting for the  
385 lack of difference between the prodromal features of MS and lupus.<sup>40</sup>

386 Several previous studies have investigated whether pre-diagnosis presentations of MS vary with  
387 age and sex.<sup>9-11</sup> One study reported higher rates of pre-diagnosis anemia in men than in women,  
388 whereas sex had no effect on the rates of pre-diagnosis fatigue and pain.<sup>9</sup> Our findings are  
389 consistent with a previous study suggesting that males had more exacerbated pre-diagnosis  
390 presentations, namely higher healthcare use and genito-urinary prescriptions (ATC level 1  
391 classification).<sup>10</sup> Another study observed that musculoskeletal diseases were more frequent for  
392 women and reproductive system diseases more frequent for males.<sup>11</sup> However, these studies  
393 used large disease categories (several groups of ICD-10 codes) or prescription categories (ATC  
394 level 1) which did not allow us to properly compare with our findings. In our study, an effect  
395 of sex was also observed when combining the observed pre-diagnosis features. Concerning the  
396 effect of age, previous findings observed a stronger effect of MS on overall healthcare in the 5  
397 years prior to the first demyelinating event for older vs. younger adults.<sup>10</sup> In our work, we only  
398 found that autonomic symptoms increased with age, though not reaching significance. Overall,  
399 diversity in the presentation of pre-diagnosis conditions was observed for males and females,

400 and across age groups which suggests that these variables should be used to investigate pre-  
401 clinical manifestations in MS.

402 The associations were weaker for diagnoses established after 2010, but this difference was not  
403 statistically significant due to the small sample size. The updated diagnostic criteria have  
404 probably decreased time to diagnosis, as shown by the four-year decrease in the UK and the  
405 two-year decrease in France for age at MS diagnosis since 2010.

406 It remains unclear whether the identified pre-clinical conditions are risk factors for MS, or  
407 nonspecific early MS symptoms. Moreover, due to the frequency of these symptoms in the  
408 general population and the non-specificity regarding prodrome form other auto-immune  
409 diseases, we should not expect that the identification of a prodrome will dramatically change  
410 clinical care, at least in the general population. We found that disclosure of MS diagnosis and  
411 evolution had a strong impact on all these associations. In large EHR databases, some time may  
412 elapse between disclosure of the diagnosis and the first record for a few patients. Given the  
413 large increase in antidepressant use at and after MS diagnosis, also reported in a previous  
414 study,<sup>39</sup> we cannot rule out the possibility that the observed association with depression can be  
415 explained by a few patients for whom the first record of MS appears several years after the first  
416 true diagnosis. Caution is therefore required in interpretation and it would probably be hasty to  
417 conclude that use of these observed prodromal associations would help to improve early  
418 diagnosis of MS.

419 Our study has several strengths. It is a fully agnostic study of the MS prodrome, based on data  
420 from two large databases in two different countries. This should ensure that the results are  
421 highly generalizable. This study also includes a comparison with the period after MS  
422 diagnosis, and a stratification for age, sex, and year of diagnosis, in line with the  
423 recommendations of previous studies.<sup>41</sup> However, like most studies based on primary care  
424 databases, it is also subject to several limitations. First, no data for potential confounding

425 factors, such as education level, ethnicity, socioeconomic status, body-mass index, or genetic  
426 information, were available. Second, UK THIN database contains slightly fewer people aged  
427 under 25 years,<sup>21</sup> possibly explaining that age at diagnosis is a bit higher than what we could  
428 expect from other epidemiological studies. Third, controls were also selected from primary  
429 care databases, therefore the control cohort did not include individuals who never consulted a  
430 general practitioner.

### 431 **Conclusion**

432

433 We performed a modern large-scale data-driven survey of a potential prodrome of MS in the  
434 primary care setting. Our findings confirm that several pre-diagnostic features of MS can be  
435 observed in large-scale electronic health record data. We also show that the prodromal  
436 presentation depends on sex and that all pre-diagnosis health conditions associated with MS  
437 were recorded more frequently in the [0-5] years after MS diagnosis compared to the [0-5] years  
438 before MS diagnosis. Future studies are required to determine whether the detection of these  
439 health conditions can help to decrease age at diagnosis of MS, although our results suggest that  
440 they are probably not sufficiently specific to define an MS prodrome.

441

442

443

444

445

446

447

448

449

450


451

452

	Size, n	Sex (female)	Age at diagnosis	Age at first symptom of MS	Person-years of data available before diagnosis	Number of visits per year before diagnosis
<b>UK</b>						
MS						
Whole cohort	15808	70.5%	46 (37 - 57)	44 (34 - 54)	9 (5 - 13)	6 (2 - 7)
Year of MS diagnosis						
<2010	10108	70.9%	48 (38 - 58)	46 (37 - 56)	7 (5 - 10)	6 (2 - 7)
[2010,2017]	4319	69.9%	44 (35-54)	41 (31 - 51)	13 (8 - 18)	6 (2 - 7)
>2017	1381	69.1%	44 (34 - 55)	39 (30 - 50)	17 (9 - 23)	5 (2 - 7)
Lupus	5296	88.2%	48 (36 - 61)		9 (5 - 14)	8 (3 - 10)
Crohn's disease	20872	54.5%	42 (27 - 59)		7 (4 - 12)	6 (2 - 8)
No MS	42226	70.2%	46 (36 - 56)		7 (4 - 12)	5 (2 - 6)
<b>France</b>						
MS						
Whole cohort	4366	70.2%	44 (34 - 54)	42 (32 - 52)	6 (3 - 10)	4 (2 - 6)
Year of MS diagnosis						
<2010	1890	69.8%	45 (35 - 55)	44 (34 - 55)	4 (3 - 6)	5 (2 - 7)
[2010,2017]	1708	70.4%	43 (34 - 52)	41 (32 - 50)	8 (4 - 11)	4 (2 - 5)
>2017	768	71.0%	43 (32 - 54)	40 (30 - 51)	10 (5 - 15)	3 (1 - 5)
Lupus	2041	81.5%	47 (36 - 60)		7 (4 - 10)	5 (2 - 7)
Crohn's disease	9605	55.9%	40 (27 - 55)		7 (4 - 11)	4 (1 - 5)
No MS	12564	70.2%	43 (33 - 53)		4 (3 - 7)	3 (1 - 4)

453 **Table 1. Characteristics of patients with MS, Crohn's disease, or lupus, and controls.** The data are

454 shown as percentage or median (IQR).



455

456 **Figure 1. ORs for significant associations in the sensitivity analysis for five years before**  
 457 **the index date.** Only significant associations both in the French and UK cohorts are shown,  
 458 with red and blue dots, respectively. The size of the dot is proportional to the period prevalence.  
 459 The period prevalence is defined as the number of diagnoses or symptoms observed over the  
 460 period divided by the number of patients at risk during the period. Bars correspond to 95% CIs  
 461 after correction for multiple comparison.

462

463

464

465

466

467

468

469

470

	Sex			Age at onset			Year of diagnosis		
	Whole cohort (No. MS : 15454 No. no MS : 26253)	Women (No. MS : 10966 No. no MS : 18821)	Men (No. MS : 4488 No. no MS : 7442)	<40 (No. MS : 5151 No. no MS : 7079)	[40,53] (No. MS : 5152 No. D no MS : 9620)	>53 (No. MS : 5151 No. no MS : 9253)	<2010 (No. MS : 10283 No. no MS : 18964)	[2010,2017] (No. MS : 4417 No. no MS : 6419)	>2017 (No. MS : 754 No. no MS : 732)
	<b>Before diagnosis</b>								
F32 : Major depressive disorder, single episode	1.34 (1.24 - 1.45)*	1.31 (1.20 - 1.43)*	1.48 (1.26 - 1.74)*	1.34 (1.16 - 1.55)*	1.36 (1.20 - 1.53)*	1.32 (1.15 - 1.51)*	1.40 (1.27 - 1.53)*	1.26 (1.10 - 1.46)*	0.90 (0.63 - 1.29)
F52 : Sexual dysfunction	1.63 (1.31 - 2.03)*	1.60 (1.05 - 2.42)*	1.61 (1.24 - 2.09)*	1.85 (1.07 - 3.18)*	1.91 (1.35 - 2.70)*	1.42 (1.01 - 1.98)*	1.69 (1.29 - 2.22)*	1.59 (1.07 - 2.34)*	.*
K59 : Constipation	1.89 (1.63 - 2.18)*	1.73 (1.47 - 2.04)*	2.55 (1.87 - 3.48)*	1.48 (1.12 - 1.96)*	1.99 (1.53 - 2.59)*	2.16 (1.73 - 2.70)*	2.05 (1.67 - 2.50)*	1.70 (1.35 - 2.14)*	1.17 (0.70 - 1.96)
N30 : Cystitis	1.39 (1.23 - 1.57)*	1.32 (1.16 - 1.49)*	2.78 (1.83 - 4.21)*	1.18 (0.95 - 1.47)	1.25 (1.02 - 1.54)*	1.72 (1.41 - 2.10)*	1.47 (1.26 - 1.71)*	1.20 (0.97 - 1.48)	1.24 (0.77 - 2.00)
N39 : Urinary tract infection, site not specified	1.38 (1.21 - 1.57)*	1.29 (1.12 - 1.48)*	2.16 (1.50 - 3.12)*	1.15 (0.89 - 1.47)	1.28 (1.02 - 1.61)*	1.65 (1.35 - 2.03)*	1.50 (1.29 - 2.22)*	1.09 (0.83 - 1.42)	1.32 (0.64 - 2.74)
<b>After diagnosis</b>									
F32 : Major depressive disorder, single episode	1.96 (1.83 - 2.11)*	1.84 (1.69 - 1.99)**	2.42 (2.09 - 2.80)*	2.12 (1.88 - 2.39)*	1.98 (1.75 - 2.23)*	1.91 (1.67 - 2.20)*	1.97 (1.81 - 2.14)*	2.0 (1.73 - 2.32)*	1.68 (1.09 - 2.61)*
F52 : Sexual dysfunction	2.84 (2.43 - 3.31)*	1.96 (1.41 - 2.73)*	3.13 (2.62 - 3.73)*	4.64 (3.34 - 6.44)*	3.98 (3.06 - 5.18)*	1.43 (1.10 - 1.85)*	2.94 (2.46 - 3.52)*	2.56 (1.87 - 3.49)*	.*
K59 : Constipation	3.36 (3.07 - 3.68)*	3.08 (2.77 - 3.42)*	4.29 (3.57 - 5.16)*	3.14 (2.62 - 3.76)*	4.14 (3.52 - 4.86)*	3.17 (2.75 - 3.65)*	3.57 (3.19 - 4.00)*	2.82 (2.40 - 3.32)*	2.65 (1.62 - 4.32)*
N30 : Cystitis	2.49 (2.29 - 2.72)*	2.2 (2.01 - 2.41)*	6.02 (4.58 - 7.93)*	2.14 (1.82 - 2.51)*	2.6 (2.24 - 3.02)*	2.84 (2.46 - 3.28)*	2.67 (2.40 - 2.96)*	2.07 (1.76 - 2.45)*	1.91 (1.23 - 2.96)*
N39 : Urinary tract infection, site not specified	2.69 (2.43 - 2.98)*	2.49 (2.23 - 2.78)*	3.92 (3.03 - 5.07)*	2.3 (1.90 - 2.79)*	2.76 (2.31 - 3.30)*	2.94 (2.50 - 3.44)*	2.77 (2.47 - 3.11)*	2.48 (1.98 - 3.11)*	3.23 (1.48 - 7.08)*

**Table 2. ORs for all health conditions individually associated with MS in the sensitivity analysis during the five years before and five years after the occurrence of the first symptoms.** Individuals with MS are compared with controls without MS. We used the whole sensitivity cohort, sex-based cohorts, age-at-onset cohorts, and year-at-diagnosis cohorts. Results are shown for the pooled data between France and UK cohorts Results from the UK and French cohorts are shown in eTable 10 and 11 respectively.

.\* cannot be calculated because too few presentations were recorded.

\* for ORs associated with corrected p-values below 0.05 or initial p-value below 0.05/5. p-value are adjusted for multiple comparisons using the Bonferroni method.

473

474

	Whole cohort (No. MS : 20174 No. no MS : 54790)	Sex		Age at onset		
		Women (No. MS : 14210 No. no MS : 38463)	Men (No. MS : 5964 No. no MS : 16309)	<40 (No. MS : 6724 No. no MS : 18263)	[40,53] (No. MS : 6724 No. no MS : 18263)	>53 (No. MS : 6726 No. no MS : 182635)
<b>Before diagnosis</b>						
At least one feature	1.41 (1.35 - 1.47)** (MS : 30.87 Control : 22.5)	1.32 (1.26 - 1.39)** (MS : 33.72 Control : 25.82)	1.7 (1.57 - 1.85)** (MS : 24.07 Control : 14.83)	1.3 (1.21 - 1.40)** (MS : 28.41 Control : 21.37)	1.41 (1.31 - 1.51)** (MS : 32.07 Control : 23.35)	1.48 (1.37 - 1.58)* (MS : 32.1 Control : 23.12)
At least two features	1.47 (1.36 - 1.59)** (MS : 7.16 Control : 4.52)	1.31 (1.20 - 1.43)* (MS : 8.05 Control : 5.64)	2.46 (2.05 - 2.95)** (MS : 5.02 Control : 1.95)	1.27 (1.10 - 1.47)* (MS : 5.83 Control : 4.08)	1.46 (1.28 - 1.67)** (MS : 7.14 Control : 4.52)	1.63 (1.44 - 1.84) (MS : 8.49 Control : 5.05)
At least three features	1.63 (1.37 - 1.93)** (MS : 1.46 Control : 0.8)	1.4 (1.16 - 1.68)** (MS : 1.67 Control : 1.05)	4.07 (2.53 - 6.55)** (MS : 0.95 Control : 0.22)	1.35 (0.94 - 1.94) (MS : 0.93 Control : 0.59)	1.49 (1.11 - 2.0)* (MS : 1.39 Control : 0.82)	1.94 (1.51 - 2.51)** (MS : 2.06 Control : 0.99)

475


476 **Table 3. ORs and prevalence in MS and non-MS cohorts (OR (95% CI) (MS :**  
477 **frequency, Control : frequency)) for combinations of at least one, two, or three health**  
478 **problems individually associated with MS in the sensitivity analysis during the five years**  
479 **before the occurrence of the first symptoms.** Individuals with MS are compared with  
480 controls without MS. We used the whole sensitivity cohort, sex-based cohorts, and age-at-  
481 onset cohorts. Results are shown for the pooled data between France and UK cohorts.

482 \* for ORs associated with corrected p-values below 0.05 or initial p-value below 0.05/113. p-  
483 value are adjusted for multiple comparisons using the Bonferroni method.

484

485

486



487

488 **Figure 2. ORs for significant associations in the sensitivity analysis for five years before**

489 **the index date in comparison to other auto-immune diseases.** Patients with MS are

490 compared to patients with lupus and Crohn's disease in pooled data from the French and UK

491 cohorts. OR > 1 indicates a higher association in MS cohort compared to Crohn's disease or

492 lupus cohort. The size of the dot is proportional to the period prevalence. The period


493 prevalence is defined as the number of diagnoses or symptoms observed over the period

494 divided by the number of patients at risk during the period. Results from the French and UK

495 cohorts individually are shown in **eFigure 3**.

496





505 **Figure 3. Period prevalence (%) of prescriptions associated with depression (A), urinary**  
 506 **tract infections (B), bacterial infections (C), and constipation (D), and mean number of**  
 507 **visits to the physician per year (E) in the pooled UK and France cohort. For a given**  
 508 **prescription, the period prevalence is defined as the number of prescriptions observed over the**  
 509 **period divided by the number of patients at risk during the period. Results from the French**  
 510 **and UK cohorts individually are shown in eFigure 4 and 5.**

511

512

513

514

515

516

517

518

519

520

521

522 **References:**

523

- 524 1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited: *Curr Opin*  
525 *Neurol.* 2002;15(3):239-245. doi:10.1097/00019052-200206000-00003
- 526 2. Bjornevik K, Munger KL, Cortese M, et al. Serum Neurofilament Light Chain Levels  
527 in Patients With Presymptomatic Multiple Sclerosis. *JAMA Neurol.* 2020;77(1):58.  
528 doi:10.1001/jamaneurol.2019.3238
- 529 3. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high  
530 prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science.*  
531 2022;375(6578):296-301. doi:10.1126/science.abj8222
- 532 4. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal  
533 Parkinson's disease: MDS Criteria for Prodromal PD. *Mov Disord.* 2015;30(12):1600-1611.  
534 doi:10.1002/mds.26431
- 535 5. Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive Decline in Prodromal  
536 Alzheimer Disease and Mild Cognitive Impairment. *ARCH NEUROL.* 2011;68(3):6.
- 537 6. Lebrun-Frenay C, Kantarci O, Siva A, et al. Radiologically Isolated Syndrome: 10-  
538 YEAR Risk Estimate of a Clinical Event. *Ann Neurol.* 2020;88(2):407-417.  
539 doi:10.1002/ana.25799
- 540 7. Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating  
541 event suggestive of a multiple sclerosis prodrome: a matched cohort study. *Lancet Neurol.*  
542 2017;16(6):445-451. doi:10.1016/S1474-4422(17)30076-5
- 543 8. Disanto G, Zecca C, MacLachlan S, et al. Prodromal symptoms of multiple sclerosis  
544 in primary care. *Ann Neurol.* 2018;83(6):1162-1173. doi:10.1002/ana.25247
- 545 9. Yusuf FL, Wijnands JM, Kingwell E, et al. Fatigue, sleep disorders, anaemia and pain  
546 in the multiple sclerosis prodrome. *Mult Scler J.* 2021;27(2):290-302.  
547 doi:10.1177/1352458520908163
- 548 10. Yusuf FLA, Wijnands JMA, Karim ME, et al. Sex and age differences in the Multiple  
549 Sclerosis prodrome. *Front Neurol.* 2022;13:1017492. doi:10.3389/fneur.2022.1017492
- 550 11. Perwieniec J, Podwójcic K, Maluchnik M, et al. Gender-Related Differences in  
551 Prodromal Multiple Sclerosis Characteristics: A 7-Year Observation Study. *J Clin Med.*  
552 2021;10(17):3821. doi:10.3390/jcm10173821
- 553 12. Gasperi C, Hapfelmeier A, Daltrozzo T, Schneider A, Donnachie E, Hemmer B.  
554 Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple  
555 Sclerosis. *Neurology.* 2021;96(24):e2977-e2988. doi:10.1212/WNL.00000000000012074
- 556 13. Bitton A, Vutcovici M, Patenaude V, Sewitch M, Suissa S, Brassard P. Epidemiology  
557 of Inflammatory Bowel Disease in Québec: Recent Trends. *Inflamm Bowel Dis.*  
558 2014;20(10):1770-1776. doi:10.1097/MIB.0000000000000162
- 559 14. Nightingale AL, Davidson JE, Molta CT, Kan HJ, McHugh NJ. Presentation of SLE in  
560 UK primary care using the Clinical Practice Research Datalink. *Lupus Sci Med.*  
561 2017;4(1):e000172. doi:10.1136/lupus-2016-000172

- 562 15. Chang JC, Mandell DS, Knight AM. High Health Care Utilization Preceding  
563 Diagnosis of Systemic Lupus Erythematosus in Youth. *Arthritis Care Res.* 2018;70(9):1303-  
564 1311. doi:10.1002/acr.23485
- 565 16. Alexandra D Frolkis, Isabelle A Vallerand, Abdel-Aziz Shaheen, et al. Depression  
566 increases the risk of inflammatory bowel disease, which may be mitigated by the use of  
567 antidepressants in the treatment of depression. *Gut.* 2019.
- 568 17. Aamir N. Dam, Adam M. Berg, Francis A. Farraye. Environmental Influences on the  
569 Onset and Clinical Course of Crohn's Disease—Part 1: An Overview of External Risk  
570 Factors. *Gastroenterology & Hepatology.* November 2013.
- 571 18. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis.  
572 *Cold Spring Harb Perspect Med.* 2019;9(4):a028944. doi:10.1101/cshperspect.a028944
- 573 19. Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a Risk Factor for  
574 Multiple Sclerosis Onset or Relapse: A Systematic Review. *Neuroepidemiology.*  
575 2011;36(2):109-120. doi:10.1159/000323953
- 576 20. Refai RH, F.Barghout M, Abou-Raya AN, Abdou MH. *Environmental Risk Factors of*  
577 *Systemic Lupus Erythematosus: A Case Control Study.* In Review; 2022. doi:10.21203/rs.3.rs-  
578 1269968/v1
- 579 21. Betina T Blak, Mary Thompson, Hassy Dattani, Alison Bourke. Generalisability of  
580 The Health Improvement Network (THIN) database: demographics, chronic disease  
581 prevalence and mortality rates. *J Innov Health Inform.* 2011.
- 582 22. Langley TE, Szatkowski L, Gibson J, et al. Validation of The Health Improvement  
583 Network (THIN) primary care database for monitoring prescriptions for smoking cessation  
584 medications: VALIDATING SMOKING CESSATION THERAPY PRESCRIBING DATA.  
585 *Pharmacoepidemiol Drug Saf.* 2010;19(6):586-590. doi:10.1002/pds.1960
- 586 23. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the  
587 health improvement network (THIN) database for pharmacoepidemiology research.  
588 *Pharmacoepidemiol Drug Saf.* 2007;16(4):393-401. doi:10.1002/pds.1335
- 589 24. Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement  
590 Network (THIN) for the study of psoriasis: Validity of THIN for the study of psoriasis. *Br J*  
591 *Dermatol.* Published online February 2011:no-no. doi:10.1111/j.1365-2133.2010.10134.x
- 592 25. Public Health England. Multiple sclerosis: prevalence, incidence and smoking status -  
593 data briefing. [https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-](https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing#fn:6)  
594 [incidence-and-smoking-status/multiple-sclerosis-prevalence-incidence-and-smoking-status-](https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing#fn:6)  
595 [data-briefing#fn:6.](https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing#fn:6) February 4, 2020.
- 596 26. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence  
597 and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General  
598 Practice Research Database. *J Neurol Neurosurg Psychiatry.* 2014;85(1):76-84.  
599 doi:10.1136/jnnp-2013-305450
- 600 27. Alonso A, Jick SS, Olek MJ, Hernán MA. Incidence of multiple sclerosis in the United  
601 Kingdom: Findings from a population-based cohort. *J Neurol.* 2007;254(12):1736-1741.  
602 doi:10.1007/s00415-007-0602-z
- 603 28. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis:  
604 2010 Revisions to the McDonald criteria. *Ann Neurol.* 2011;69(2):292-302.  
605 doi:10.1002/ana.22366
- 606 29. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017  
607 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17(2):162-173. doi:10.1016/S1474-  
608 4422(17)30470-2
- 609 30. Brownlee WJ, Swanton JK, Altmann DR, Ciccarelli O, Miller DH. Earlier and more  
610 frequent diagnosis of multiple sclerosis using the McDonald criteria: Figure 1. *J Neurol*  
611 *Neurosurg Psychiatry.* 2015;86(5):584-585. doi:10.1136/jnnp-2014-308675

- 612 31. Schwenkenbecher P, Wurster U, Konen FF, et al. Impact of the McDonald Criteria  
613 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. *Front Neurol.*  
614 2019;10:188. doi:10.3389/fneur.2019.00188
- 615 32. Wijnands JM, Zhu F, Kingwell E, et al. Five years before multiple sclerosis onset:  
616 Phenotyping the prodrome. *Mult Scler J.* 2019;25(8):1092-1101.  
617 doi:10.1177/1352458518783662
- 618 33. Disanto G, Zecca C, MacLachlan S, et al. Prodromal symptoms of multiple sclerosis  
619 in primary care. *Ann Neurol.* 2018;83(6):1162-1173. doi:10.1002/ana.25247
- 620 34. Högg T, Wijnands JMA, Kingwell E, et al. Mining healthcare data for markers of the  
621 multiple sclerosis prodrome. *Mult Scler Relat Disord.* 2018;25:232-240.  
622 doi:10.1016/j.msard.2018.08.007
- 623 35. August M Bakke, Marit Grønning, Kjell-Morten Myhr. Bladder, bowel and sexual  
624 dysfunction in patients with multiple sclerosis--a cohort study. *Scand J Urol Nephrol Suppl.*  
625 Published online February 1996.
- 626 36. DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis:  
627 better understanding and improved therapies. *Curr Opin Neurol.* 2002;15(3):271-278.  
628 doi:10.1097/00019052-200206000-00008
- 629 37. Nortvedt MW, Riise T, Frugaård J, et al. Prevalence of bladder, bowel and sexual  
630 problems among multiple sclerosis patients two to five years after diagnosis. *Mult Scler J.*  
631 2007;13(1):106-112. doi:10.1177/1352458506071210
- 632 38. Berger JR, Pocoski J, Preblick R, Boklage S. Fatigue heralding multiple sclerosis.  
633 *Mult Scler J.* 2013;19(11):1526-1532. doi:10.1177/1352458513477924
- 634 39. Marrie RA, Walld R, Bolton JM, et al. Rising incidence of psychiatric disorders before  
635 diagnosis of immune-mediated inflammatory disease. *Epidemiol Psychiatr Sci.*  
636 2019;28(03):333-342. doi:10.1017/S2045796017000579
- 637 40. Frazzei G, van Vollenhoven RF, de Jong BA, Siegelaa SE, van Schaardenburg D.  
638 Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus  
639 Erythematosus, Multiple Sclerosis and Type 1 Diabetes. *Front Immunol.* 2022;13:899372.  
640 doi:10.3389/fimmu.2022.899372
- 641 41. Tremlett H, Munger KL, Makhani N. The Multiple Sclerosis Prodrome: Evidence to  
642 Action. *Front Neurol.* 2022;12:761408. doi:10.3389/fneur.2021.761408
- 643

644

645

646

647

648 **Contributors** OG, TN, CL and SD conceived and designed the study. LG extracted the data.

649 LG and OG ensured data quality and OG, TN, CL and SD analysed the data. OG and TN

650 generated the figures. OG, LG, BL, CL and SD interpreted the results and contributed to the

651 writing of the final version of the manuscript. All authors agreed with the results and

652 conclusions and approved the final draft.

653

654 **Competing interest** CL has received consulting or travel fees from Biogen, Novartis, Roche,  
655 Sanofi, Teva and Merck Serono, none related to the present work. LG and BL are full time  
656 employees of Cegedim.

657

658 **Data sharing statement** The data used in the preparation of the article are available from the  
659 Cegedim company upon reasonable request ([info@the-health-improvement-network.co.uk](mailto:info@the-health-improvement-network.co.uk)).

660

661 **Acknowledgment** The research leading to these results has received funding from the joint  
662 program in neurodegenerative diseases (JPND) ANR-21-JPW2-0002-01 (LeMeReND) and  
663 the program "Investissements d'avenir" ANR-10-IAIHU-06. This work was funded in part by  
664 the French government under management of Agence Nationale de la Recherche as part of the  
665 "Investissements d'avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute).  
666 Editorial support, in the form of medical writing and copyediting, was provided by Julie  
667 Sappa of Alex Edelman and Associates.

668

669 **Ethics committee approval** Approval was sorted before carrying out this study (and for the  
670 use of datasets). The study was a retrospective analysis of secondary anonymised patient data  
671 only. For the UK database, data is only available to researchers carrying out approved medical  
672 research. Ethical approval was granted by the NHS South-East Multicentre Research Ethics  
673 Committee in 2003 (ref: 03/01/073) for establishment of the THIN database, and it was  
674 updated in 2011. A further update and approval was granted in 2020 by the NHS South  
675 Central, Oxford C Research Ethics Committee (Ref: 20/SC/0011). For the French Database,  
676 several audits were conducted by CNIL (Commission Nationale de l'Informatique et des  
677 Libertés, the French authority responsible for the protection of personal data). Data are

678 available from the GERS SAS for researchers who meet the criteria for access to confidential  
679 data. Researchers willing to replicate the results should address a request to the Cegedim  
680 company (info@the-health-improvement-network.co.uk). The study was approved by the  
681 THIN Scientific Research Committee (SRC) on 4th Feb 2022 (SRC reference 21-016).

682 **Patient and Public involvement** We plan to disseminate the results of our research to the  
683 public and relevant patient community through the current publication and its related press  
684 release as well as presentations at scientific conferences.

685

686 The lead authors (CL, SD) affirm that this manuscript is an honest, accurate, and transparent  
687 account of the study being reported; that no important aspects of the study have been omitted;  
688 and that any discrepancies from the study as planned (and, if relevant, registered) have been  
689 explained.

690

691

692

693

694

695

696

697

698

699

700

701

702

# Supplementary materials

703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727

## TABLE OF CONTENTS

- **Supplementary method.** Details on data collection in THIN database
- **eTable 1.** Health conditions suggestive of a demyelinating claim
- **eTable 2.** Health conditions suggestive of a MS relapse and positively associated with a future diagnosis of MS either in the French or British database
- **eFigure 4.** Patient selection flowchart for the French study
- **eFigure 5.** Patient selection flowchart for the UK study
- **eTable 3.** Proportion (%) of patients with at least one record of the conditions tested in the control populations in France and the UK at 5 years before the diagnosis
- **eTable 4.** Prescriptions linked to diagnoses in the French database
- **eTable 5.** ORs for all health conditions in over 0.5% of patients and controls individually associated with a future symptom specific of MS at 5 years before the index date
- **eTable 6.** ORs for all health conditions individually associated with a future diagnosis of MS for the five-year period leading up to the index date
- **eTable 7.** Pooled, UK, and French ORs for all health problems individually associated with MS in the sensitivity analysis during the five years before the occurrence of the first symptoms
- **eTable 8.** Characteristics of patients with MS and individuals without MS with at least five years of data before the index date in the two cohorts
- **eTable 9.** Characteristics of patients with MS and individuals without MS with at least two years of data before and after the index date in the two cohorts
- **eTable 10.** ORs in the UK cohort for all health conditions individually associated with MS in the sensitivity analysis during the five years before and five years after the occurrence of the first symptoms

- 728 - **eTable 11.** ORs in the French cohort for all health conditions individually associated with MS  
729 in the sensitivity analysis during the five years before and five years after the occurrence of  
730 the first symptoms
- 731 - **eFigure 3.** ORs for significant associations in the sensitivity analysis for five years before the  
732 index date in comparison to other auto-immune diseases
- 733 - **eFigure 6.** Period prevalence (%) of prescriptions associated with depression (A), urinary tract  
734 infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the  
735 physician per year (E) in the UK cohort
- 736 - **eFigure 5.** Period prevalence (%) of prescriptions associated with depression (A), urinary tract  
737 infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the  
738 physician per year (E) in the French cohort.
- 739 - **eFigure 6.** Period prevalence (%) of prescriptions associated with depression (A), urinary tract  
740 infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the  
741 physician per year (E) in the pooled cohort, 15 years before diagnosis
- 742 - **eFigure 7.** Period prevalence (%) of prescriptions associated with depression (A), urinary tract  
743 infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the  
744 physician per year (E) in the pooled cohort, 5 years before diagnosis up to 10 years after  
745 diagnosis



746 **Supplementary method:** Details on data collection in THIN database

747

748 French data were collected from a pool of 2500 general practitioners (GP),<sup>1</sup> and were  
749 representative of the French population in terms of age, sex, and area of residence.<sup>2</sup> UK data  
750 were collected from 400 general practices covering about 6% of the UK population, selected  
751 for the THIN quality data-recording scheme with Vision practice management software.<sup>3</sup>  
752 Several studies have already reported that the electronically coded diagnoses in this database  
753 are representative of the UK general practice population in terms of demographics and type of  
754 consultation.<sup>4</sup> For each patient, diagnosis corresponding to each visit, prescriptions made by  
755 the GP, and all other diagnoses associated with these prescriptions were available. Data for  
756 education level and social status were not provided, to preserve anonymity.

757 1. Iordache L, Strazzulla A, Lekens B, Bergmann J, Diamantis S. Évaluation du suivi des  
758 recommandations de prise en charge des infections urinaires en médecine de ville en France.  
759 *Médecine et Maladies Infectieuses*. 2018;48(4):S101-S102.

760 doi:10.1016/j.medmal.2018.04.253

761 2. Kopp A, Mangin O, Gantzer L, et al. Pneumococcal vaccination coverage in France by  
762 general practitioners in adults with a high risk of pneumococcal disease. *Hum Vaccin*  
763 *Immunother*. January 2, 2021:162-169.

764 3. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of  
765 Parkinson's disease in primary care: a case-control study. *The Lancet Neurology*.  
766 2015;14(1):57-64. doi:10.1016/S1474-4422(14)70287-X

767 4. Blak B, Thompson M, Dattani H, Bourke A. Generalisability of The Health  
768 Improvement Network (THIN) database: demographics, chronic disease prevalence and  
769 mortality rates. *Journal of Innovation in Health Informatics*. 2011;19(4):251-255.

770 doi:10.14236/jhi.v19i4.820

771

772

773 **eTable 1. Health conditions suggestive of a demyelinating claim**

Encephalitis, myelitis, encephalomyelitis (G04, G05)

Sequelae of inflammatory diseases of central nervous system (G09)

Demyelinating diseases of the CNS (G36, G37)

Retrobulbar neuritis and other disorders of the optic nerve and the visual pathways (H46, H47, H48)

774

775

776 ***eTable 2. Health conditions suggestive of a MS relapse and positively associated with a future diagnosis of***  
777 ***MS either in the French or British database.***

Paresthesia of skin (R20)

Tetany (R29)

Dizziness and giddiness (R42)

Abnormal and involuntary movement (R25)

Carpal tunnel syndrome (G56)

Disorders of vestibular function (H81)


Visual disturbances (H53)

Contracture of muscle (M62)

778


779

780  
781



782  
783  
784

**eFigure 7. Patient selection flowchart for the French study.** Note: the index date for controls is taken as the last contact date recorded during the year of contact selected randomly



785  
786  
787

**eFigure 8. Patient selection flowchart for the UK study.** Note: the index date for controls is taken as the last contact date recorded during the year of contact selected randomly

788  
789

790  
791  
792

**eTable 3. Proportion (%) of patients with at least one record of the conditions tested in the control populations in France and the UK at 5 years before the diagnosis. The 113 ICD10 codes that were recorded with a relative frequency of more than 0.5 % in both countries were considered.**

	FR Controls (UK) n=42266	UK Controls (FR) n=12564
B00 : Herpesviral [herpes simplex] infections	3.36	2.02
B02 : Zoster	1.73	0.84
B07 : Viral warts	3.11	0.73
B34 : Viral infection of unspecified site	2.12	2.08
B35 : Dermatophytosis	5.5	2.39
B37 : Candidiasis	5.54	2.63
D50 : Iron deficiency anemia	1.89	1.09
D64 : Other anemias	0.73	0.97
E03 : Other hypothyroidism	4.51	2.39
E11 : Type 2 diabetes mellitus	3.77	2.45
E14 : Other diabetes	1.71	0.76
E66 : Overweight and obesity	1.48	1.88
E78 : Disorders of lipoprotein metabolism and other lipidemias	9.02	6.51
F10 : Alcohol related disorders	1.19	0.59
F32 : Major depressive disorder, single episode	19.65	10.75
F40 : Phobic anxiety disorders	0.88	1.19
F41 : Other anxiety disorders	8.43	10.27
F43 : Reaction to severe stress	1.49	3.3
F52 : Sexual dysfunction	1.54	1.96
G40 : Epilepsy and recurrent seizures	0.86	0.57
G43 : Migraine	4.7	4.9
G47 : Sleep disorders	1.92	6.47
G56 : Carpal tunnel syndrome	1.45	1.13
H00 : Hordeolum and chalazion	1.59	0.85
H10 : Conjunctivitis	6.02	4.21
H60 : Otitis externa	4.53	1.89
H61 : Other disorders of external ear	3.11	0.93
H66 : Suppurative and unspecified otitis media	2.2	5.1
H81 : Disorders of vestibular function	1.32	1.47
H92 : Otagia and effusion of ear	2.51	3.01
H93 : Other disorders of ear	1.03	1.05
I10 : Essential (primary) hypertension	13.7	10.51
I20 : Angina pectoris	1.14	0.58
I80 : Phlebitis and thrombophlebitis	1.09	0.71
I83 : Varicose veins of lower extremities	1.97	1.14
I84 : Hemorrhoids	6.62	3.37
J00 : Acute nasopharyngitis [common cold]	2.71	24.56
J01 : Acute sinusitis	5.7	9.52

J02 : Acute pharyngitis	6.52	17.18
J04 : Acute laryngitis and tracheitis	1.8	11.36
J11 : Influenza due to unidentified influenza virus	2.97	11.58
J20 : Acute bronchitis	2.54	9.62
J30 : Vasomotor and allergic rhinitis	5.0	2.71
J31 : Chronic rhinitis, nasopharyngitis and pharyngitis	1.17	2.16
J32 : Chronic sinusitis	0.69	0.82
J34 : Other and unspecified disorders of nose and nasal sinuses	1.17	2.11
J40 : Bronchitis	0.6	3.53
J45 : Asthma	7.99	5.07
K04 : Diseases of pulp and periapical tissues	1.06	1.03
K12 : Stomatitis and related lesions	0.98	0.9
K21 : Gastro-esophageal reflux disease	2.76	4.86
K29 : Gastritis and duodenitis	1.66	3.42
K30 : Functional dyspepsia	3.72	1.1
K44 : Diaphragmatic hernia	1.24	5.91
K58 : Irritable bowel syndrome	3.42	4.25
K59 : Functional intestinal disorders	4.37	5.22
K62 : Other diseases of anus and rectum	2.44	0.9
K80 : Cholelithiasis	0.89	0.85
L02 : Cutaneous abscess, furuncle and carbuncle	2.21	1.55
L03 : Cellulitis and acute lymphangitis	3.43	0.89
L21 : Seborrheic dermatitis	1.44	0.6
L29 : Pruritus	2.43	3.17
L30 : Other and unspecified dermatitis	4.74	4.8
L40 : Psoriasis	2.07	1.13
L50 : Urticaria	1.69	1.0
L65 : Other nonscarring hair loss	0.98	1.05
L70 : Acne	3.51	1.6
L98 : Other disorders of skin and subcutaneous tissue	4.61	0.94
M10 : Gout	1.11	0.53
M13 : Other arthritis	1.16	0.89
M19 : Other and unspecified osteoarthritis	3.09	3.77
M25 : Pain in joint	8.05	8.63
M47 : Spondylosis	1.3	1.82
M51 : Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders	0.84	0.93
M53 : Cervicobrachial syndrome	0.73	2.82
M54 : Dorsalgia	15.5	24.57
M62 : Contracture of muscle	0.63	2.09
M75 : Shoulder lesions	2.53	5.6
M77 : Other enthesopathies	3.31	6.11
M79 : Pain in limb, foot / Myalgia	14.24	8.77
M81 : Osteoporosis without current pathological fracture	0.96	0.98



N30 : Cystitis	6.99	6.81
N39 : Urinary tract infection, site not specified	5.36	2.77
N64 : Other disorders of breast	2.72	0.9
N76 : Other inflammation of vagina and vulva	1.25	1.17
N91 : Absent, scanty and rare menstruation	2.23	1.44
N92 : Excessive, frequent and irregular menstruation	7.58	1.72
N94 : Pain and other conditions associated with female genital organs and menstrual cycle	2.33	1.52
N95 : Menopausal and other perimenopausal disorders	4.91	3.13
R05 : Cough	0.83	16.59
R06 : Abnormalities of breathing	1.36	1.93
R07 : Pain in throat and chest	2.0	3.92
R10 : Abdominal and pelvic pain	4.93	12.45
R20 : Paresthesia of skin	0.86	0.82
R21 : Rash and other nonspecific skin eruption	2.35	1.13
R25 : Abnormal involuntary movements	1.25	1.33
R42 : Dizziness and giddiness	3.95	3.31
R51 : Headache	2.0	7.23
R52 : Pain, unspecified	0.99	4.52
R53 : Malaise and fatigue	1.64	12.53
R55 : Syncope and collapse	0.94	0.85
R59 : Enlarged lymph nodes	0.65	1.54
R60 : Edema, not elsewhere classified	0.92	1.32
R63 : Abnormal weight loss or gain	0.68	1.32
S83 : Dislocation and sprain of joints and ligaments of knee	0.78	0.87
S93 : Dislocation and sprain of joints and ligaments at ankle; foot and toe level	1.32	2.39
T14 : Injury of unspecified body region	3.55	8.27
T78 : Adverse effects, not elsewhere classified	1.56	8.34
Z01 : Encounter for other special examination without complaint, suspected or reported diagnosis	0.6	1.63
Z02 : Encounter for administrative examination	3.61	11.89
Z13 : Encounter for screening for other diseases and disorders	0.75	2.09
Z30 : Encounter for contraceptive management	14.1	8.36
Z76 : Persons encountering health services in other circumstances	1.5	10.29

793  
794  
795

796  
797  
798

**eTable 4. Prescriptions linked to diagnoses in the French database.** Prescriptions are deemed as linked when they were given to more than 80 different people, and given in more than one out of three times for a particular diagnosis/symptom

ATC codes	ICD-10 codes
Ispaghula (psylla seeds) (A06AC01)	Other functional intestinal disorders (K59)
Macrogol (A06AD15)	Other functional intestinal disorders (K59)
Macrogol, combinations (A06AD65)	Other functional intestinal disorders (K59)
Enema combinations (A06AG20)	Other functional intestinal disorders (K59)
Carbon dioxide producing drugs (A06AX02)	Other functional intestinal disorders (K59)
Amphotericin B (A07AA07)	Candidiasis (B37)
Insulin glargine (A10AE04)	Type 2 diabetes mellitus (E11)
Metformin (A10BA02)	Type 2 diabetes mellitus (E11)
Gliclazide (A10BB09)	Type 2 diabetes mellitus (E11)
Glimepiride (A10BB12)	Type 2 diabetes mellitus (E11)
Metformin and sitagliptin (A10BD07)	Type 2 diabetes mellitus (E11)
Sitagliptin (A10BH01)	Type 2 diabetes mellitus (E11)
Repaglinide (A10BX02)	Type 2 diabetes mellitus (E11)
Vitamins, other combinations (A11JC)	Other nonscarring hair loss (L65)
Tranexamic acid (B02AA02)	Excessive, frequent and irregular menstruation (N92)
Hydrochlorothiazide (C03AA03)	Essential (primary) hypertension (I10)
Indapamide (C03BA11)	Essential (primary) hypertension (I10)
Spironolactone (C03DA01)	Essential (primary) hypertension (I10)
Other agents for treatment of hemorrhoids and anal fissures for topical use in ATC (C05AX)	Hemorrhoids (I84)
Other preparations, combinations (C05AX03)	Hemorrhoids (I84)
Rutoside, combinations (C05CA51)	Other disorders of veins (I87)
Atenolol (C07AB03)	Essential (primary) hypertension (I10)
Acebutolol (C07AB04)	Essential (primary) hypertension (I10)
Bisoprolol (C07AB07)	Essential (primary) hypertension (I10)
Celiprolol (C07AB08)	Essential (primary) hypertension (I10)
Nebivolol (C07AB12)	Essential (primary) hypertension (I10)
Amlodipine (C08CA01)	Essential (primary) hypertension (I10)
Nicardipine (C08CA04)	Essential (primary) hypertension (I10)
Lercanidipine (C08CA13)	Essential (primary) hypertension (I10)
Perindopril (C09AA04)	Essential (primary) hypertension (I10)
Ramipril (C09AA05)	Essential (primary) hypertension (I10)
Perindopril and diuretics (C09BA04)	Essential (primary) hypertension (I10)
Losartan (C09CA01)	Essential (primary) hypertension (I10)
Valsartan (C09CA03)	Essential (primary) hypertension (I10)
Irbesartan (C09CA04)	Essential (primary) hypertension (I10)
Candesartan (C09CA06)	Essential (primary) hypertension (I10)
Telmisartan (C09CA07)	Essential (primary) hypertension (I10)
Olmесartan medoxomil (C09CA08)	Essential (primary) hypertension (I10)
Losartan and diuretics (C09DA01)	Essential (primary) hypertension (I10)

Valsartan and diuretics (C09DA03)	Essential (primary) hypertension (I10)
Irbesartan and diuretics (C09DA04)	Essential (primary) hypertension (I10)
Valsartan and amlodipine (C09DB01)	Essential (primary) hypertension (I10)
Simvastatin (C10AA01)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Pravastatin (C10AA03)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Fluvastatin (C10AA04)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Atorvastatin (C10AA05)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Rosuvastatin (C10AA07)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Fenofibrate (C10AB05)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Ezetimibe (C10AX09)	Disorders of lipoprotein metabolism and other lipidemias (E78)
Amorolfine (D01AE16)	Dermatophytosis (B35)
Terbinafine (D01BA02)	Dermatophytosis (B35)
Calcipotriol, combinations (D05AX52)	Psoriasis (L40)
Aciclovir (D06BB03)	Herpesviral [herpes simplex] infections (B00)
Metronidazole (D06BX01)	Rosacea (L71)
Benzoyl peroxide (D10AE01)	Acne (L70)
Erythromycin (D10AF02)	Acne (L70)
Wart and anti-corn preparations (D11AF)	Viral warts (B07)
Other gynecologicals in ATC (G02CX)	Menopausal and other perimenopausal disorders (N95)
Levonorgestrel and ethinylestradiol (G03AA07)	Encounter for contraceptive management (Z30)
Desogestrel and ethinylestradiol (G03AA09)	Encounter for contraceptive management (Z30)
Gestodene and ethinylestradiol (G03AA10)	Encounter for contraceptive management (Z30)
Drospirenone and ethinylestradiol (G03AA12)	Encounter for contraceptive management (Z30)
Levonorgestrel and ethinylestradiol (G03AB03)	Encounter for contraceptive management (Z30)
Levonorgestrel (G03AC03)	Encounter for contraceptive management (Z30)
Desogestrel (G03AC09)	Encounter for contraceptive management (Z30)
Estradiol (G03CA03)	Menopausal and other perimenopausal disorders (N95)
Cyproterone and estrogen (G03HB01)	Encounter for contraceptive management (Z30)
Tadalafil (G04BE08)	Sexual dysfunction not caused by organic disorder or disease (F52)
Tamsulosin (G04CA02)	Benign prostatic hyperplasia (N40)
Levothyroxine sodium (H03AA01)	Other hypothyroidism (E03)
Pivmecillinam (J01CA08)	Cystitis (N30)
Phenoxymethylpenicillin (J01CE02)	Acute pharyngitis (J02)
Norfloxacin (J01MA06)	Cystitis (N30)
Moxifloxacin (J01MA14)	Acute sinusitis (J01)
Nitrofurantoin (J01XE01)	Cystitis (N30)
Fosfomycin (J01XX01)	Cystitis (N30)
Aciclovir (J05AB01)	Herpesviral [herpes simplex] infections (B00)
Oseltamivir (J05AH02)	Influenza due to unidentified influenza virus (J11)
Pneumococcus, purified polysaccharides antigen (J07AL01)	Need for immunization against other single infectious diseases (Z26)
Tetanus toxoid (J07AM01)	Need for immunization against other single infectious diseases (Z26)
Typhoid, purified polysaccharide antigen (J07AP03)	Need for immunization against other single infectious diseases (Z26)
Hepatitis B, purified antigen (J07BC01)	Need for immunization against other single infectious diseases (Z26)

Hepatitis A, inactivated, whole virus (J07BC02)	Need for immunization against other single infectious diseases (Z26)
Measles, combinations with mumps and rubella, live attenuated (J07BD52)	Need for immunization against other single infectious diseases (Z26)
Papillomavirus (human types 6, 11, 16, 18) (J07BM01)	Need for immunization against other single infectious diseases (Z26)
Diphtheria-poliomyelitis-tetanus (J07CA01)	Need for immunization against other single infectious diseases (Z26)
Diphtheria-pertussis-poliomyelitis-tetanus (J07CA02)	Need for immunization against other single infectious diseases (Z26)
Meloxicam (M01AC06)	Dorsalgia (M54)
Methocarbamol (M03BA03)	Dorsalgia (M54)
Colchicine (M04AC01)	Gout (M10)
Risedronic acid (M05BA07)	Osteoporosis without current pathological fracture (M81)
Sumatriptan (N02CC01)	Migraine (G43)
Naratriptan (N02CC02)	Migraine (G43)
Zolmitriptan (N02CC03)	Migraine (G43)
Almotriptan (N02CC05)	Migraine (G43)
Eletriptan (N02CC06)	Migraine (G43)
Frovatriptan (N02CC07)	Migraine (G43)
Loprazolam (N05CD11)	Sleep disorders (G47)
Fluoxetine (N06AB03)	Major depressive disorder, single episode (F32)
Citalopram (N06AB04)	Major depressive disorder, single episode (F32)
Paroxetine (N06AB05)	Major depressive disorder, single episode (F32)
Sertraline (N06AB06)	Major depressive disorder, single episode (F32)
Escitalopram (N06AB10)	Major depressive disorder, single episode (F32)
Mianserin (N06AX03)	Major depressive disorder, single episode (F32)
Mirtazapine (N06AX11)	Major depressive disorder, single episode (F32)
Venlafaxine (N06AX16)	Major depressive disorder, single episode (F32)
Duloxetine (N06AX21)	Major depressive disorder, single episode (F32)
Varenicline (N07BA03)	Nicotine dependence (F17)
Bethahistine (N07CA01)	Dizziness and giddiness (R42)
Proguanil, combinations (P01BB51)	Persons encountering health services for other counseling and medical advice, not elsewhere classified (Z71)
Ivermectin (P02CF01)	Scabies (B86)
Benzyl benzoate (P03AX01)	Scabies (B86)
Dexamethasone, combinations (R01AD53)	Acute nasopharyngitis [common cold] (J00)
Other nasal preparation combinations in ATC (R01AX30)	Acute nasopharyngitis [common cold] (J00)
Pseudoephedrine (R01BA02)	Acute nasopharyngitis [common cold] (J00)
Fusafungine (R02AB03)	Acute nasopharyngitis [common cold] (J00)
Terbutaline (R03AC03)	Asthma (J45)
Formoterol (R03AC13)	Asthma (J45)
Salmeterol and fluticasone (R03AK06)	Asthma (J45)
Montelukast (R03DC03)	Asthma (J45)
OTHER COLD PREPARATIONS in ATC (R05X)	Acute nasopharyngitis [common cold] (J00)
Tobramycin (S01AA12)	Conjunctivitis (H10)
Fusidic acid (S01AA13)	Conjunctivitis (H10)
Azithromycin (S01AA26)	Conjunctivitis (H10)
Sodium borate (S01AX07)	Conjunctivitis (H10)

799  
800  
801

Indifferent preparations, otologicals (S02DC)

Other disorders of external ear (H61)

802 **eTable 5. ORs for all health conditions in over 0.5% of patients and controls individually associated with a**  
 803 **future symptom specific of MS at 5 years before the index date. In the primary analysis, we used the first**  
 804 **recorded demyelinating event as the index date, while in the sensitivity analysis, we used the first symptom**  
 805 **suggestive of MS as the index date. \* cannot be calculated because too few presentations were recorded (health**  
 806 **conditions defined by ICD-10 codes with a relative frequency of less than 0.5). ORs and p-value are adjusted for**  
 807 **multiple comparisons using the Bonferroni method. P-values greater to 1 are clipped to 1.**

	Primary analysis				Sensitivity analysis			
	OR (Adjusted 95% CI)	FR Adjusted p value	OR (Adjusted 95% CI)	UK Adjusted p value	OR (Adjusted 95% CI)	FR Adjusted p value	OR (Adjusted 95% CI)	UK Adjusted p value
B00 : Herpesviral [herpes simplex] infections	1.36 (0.89 - 2.08)	1	1.02 (0.84 - 1.24)	1	1.06 (0.66 - 1.73)	1	1.0 (0.80 - 1.24)	1
B02 : Zoster	2.59 (1.49 - 4.51)	<0.0001	0.93 (0.70 - 1.23)	1	1.32 (0.66 - 2.64)	1	0.85 (0.62 - 1.16)	1
B07 : Viral warts	1.51 (0.76 - 2.98)	1	0.74 (0.59 - 0.93)	0.0001	1.13 (0.52 - 2.46)	1	0.82 (0.65 - 1.03)	0.159
B34 : Viral infection of unspecified site	1.4 (0.92 - 2.13)	0.38	1.0 (0.77 - 1.28)	1	1.4 (0.89 - 2.20)	0.731	0.96 (0.73 - 1.25)	1
B35 : Dermatophytosis	1.5 (1.03 - 2.20)	0.009	0.89 (0.76 - 1.05)	1	1.29 (0.84 - 1.98)	1	0.88 (0.74 - 1.05)	1
B37 : Candidiasis	1.58 (1.10 - 2.27)	0.0003	0.88 (0.74 - 1.03)	0.397	1.35 (0.89 - 2.04)	0.958	0.82 (0.69 - 0.98)	0.006
D50 : Iron deficiency anemia	1.82 (1.07 - 3.10)	0.004	0.8 (0.60 - 1.06)	0.537	1.71 (0.97 - 3.03)	0.059	0.73 (0.53 - 1.00)	0.03
D64 : Other anemias	1.3 (0.70 - 2.42)	1	1.04 (0.69 - 1.59)	1	1.02 (0.49 - 2.11)	1	1.0 (0.63 - 1.58)	1
E03 : Other hypothyroidism	1.35 (0.90 - 2.00)	0.771	1.0 (0.84 - 1.19)	1	1.28 (0.82 - 1.99)	1	1.01 (0.84 - 1.21)	1
E11 : Type 2 diabetes mellitus	1.56 (1.07 - 2.28)	0.001	0.76 (0.62 - 0.93)	<0.0001	1.27 (0.82 - 1.96)	1	0.78 (0.62 - 0.97)	0.003
E14 : Other diabetes	0.9 (0.41 - 1.98)	1	0.85 (0.63 - 1.14)	1	0.76 (0.31 - 1.87)	1	0.89 (0.65 - 1.22)	1
E66 : Overweight and obesity	1.25 (0.79 - 1.99)	1	0.73 (0.53 - 1.03)	0.076	1.26 (0.78 - 2.04)	1	0.66 (0.46 - 0.96)	0.005
E78 : Disorders of lipoprotein metabolism and other lipidemias	1.27 (0.99 - 1.64)	0.053	0.85 (0.75 - 0.97)	0.0003	1.07 (0.81 - 1.42)	1	0.8 (0.69 - 0.92)	<0.0001
F10 : Alcohol related disorders	1.38 (0.63 - 3.05)	1	0.55 (0.36 - 0.84)	<0.0001	*	*	0.51 (0.32 - 0.81)	<0.0001
F32 : Major depressive disorder, single episode	1.84 (1.52 - 2.21)	<0.0001	1.24 (1.14 - 1.36)	<0.0001	1.62 (1.32 - 1.98)	<0.0001	1.22 (1.11 - 1.34)	<0.0001
F40 : Phobic anxiety disorders	1.84 (1.09 - 3.09)	0.001	0.87 (0.58 - 1.31)	1	1.56 (0.92 - 2.66)	0.233	0.73 (0.45 - 1.16)	1
F41 : Other anxiety disorders	1.57 (1.29 - 1.91)	<0.0001	0.85 (0.74 - 0.98)	0.001	1.4 (1.13 - 1.73)	<0.0001	0.78 (0.67 - 0.91)	<0.0001
F43 : Reaction to severe stress	1.69 (1.23 - 2.32)	<0.0001	0.83 (0.60 - 1.15)	1	1.47 (1.05 - 2.07)	0.003	0.8 (0.58 - 1.12)	1
F52 : Sexual dysfunction	1.92 (1.29 - 2.86)	<0.0001	1.54 (1.19 - 1.99)	<0.0001	1.69 (1.10 - 2.62)	0.0008	1.47 (1.11 - 1.95)	<0.0001
G40 : Epilepsy and recurrent seizures	2.54 (1.30 - 4.97)	<0.0001	1.43 (1.00 - 2.04)	0.021	*	*	1.46 (1.00 - 2.12)	0.022
G43 : Migraine	1.55 (1.18 - 2.03)	<0.0001	1.12 (0.95 - 1.32)	1	1.21 (0.89 - 1.65)	1	1.07 (0.89 - 1.28)	1
G47 : Sleep disorders	1.64 (1.30 - 2.08)	<0.0001	1.07 (0.82 - 1.39)	1	1.36 (1.04 - 1.78)	0.002	1.01 (0.76 - 1.34)	1
G56 : Carpal tunnel syndrome	2.64 (1.64 - 4.22)	<0.0001	1.26 (0.95 - 1.67)	0.304	*	*	*	*
H00 : Hordeolum and chalazion	2.53 (1.47 - 4.36)	<0.0001	0.92 (0.68 - 1.23)	1	2.08 (1.12 - 3.83)	0.001	0.91 (0.66 - 1.26)	1
H10 : Conjunctivitis	1.42 (1.05 - 1.91)	0.002	0.85 (0.73 - 1.00)	0.026	1.28 (0.93 - 1.77)	0.514	0.82 (0.70 - 0.98)	0.003
H60 : Otitis externa	1.45 (0.94 - 2.24)	0.184	0.85 (0.71 - 1.02)	0.146	1.49 (0.93 - 2.37)	0.195	0.76 (0.62 - 0.93)	<0.0001
H61 : Other disorders of external ear	1.58 (0.87 - 2.85)	0.576	1.0 (0.81 - 1.23)	1	1.28 (0.66 - 2.50)	1	0.94 (0.75 - 1.17)	1
H66 : Suppurative and unspecified otitis media	1.45 (1.11 - 1.91)	<0.0001	0.87 (0.68 - 1.13)	1	1.32 (0.98 - 1.76)	0.054	0.93 (0.71 - 1.22)	1
H81 : Disorders of vestibular function	2.22 (1.44 - 3.43)	<0.0001	1.49 (1.13 - 1.97)	<0.0001	*	*	*	*
H92 : Otalgia and effusion of ear	1.59 (1.13 - 2.23)	<0.0001	0.9 (0.71 - 1.14)	1	1.5 (1.03 - 2.18)	0.007	0.8 (0.62 - 1.04)	0.24
H93 : Other disorders of ear, not elsewhere classified	1.38 (0.77 - 2.46)	1	1.02 (0.71 - 1.45)	1	0.87 (0.42 - 1.82)	1	0.78 (0.51 - 1.20)	1
I10 : Essential (primary) hypertension	1.28 (1.05 - 1.57)	0.0006	0.79 (0.70 - 0.88)	<0.0001	1.09 (0.87 - 1.37)	23.439	0.78 (0.69 - 0.88)	<0.0001
I20 : Angina pectoris	1.15 (0.49 - 2.70)	1	0.86 (0.60 - 1.24)	1	0.98 (0.38 - 2.52)	1	0.78 (0.53 - 1.16)	1
I80 : Phlebitis and thrombophlebitis	1.65 (0.84 - 3.24)	0.817	0.93 (0.65 - 1.33)	1	1.31 (0.57 - 3.01)	1	0.92 (0.62 - 1.35)	1

I83 : Varicose veins of lower extremities	1.47 (0.84 - 2.55)	1	0.67 (0.50 - 0.91)	<0.0001	1.32 (0.72 - 2.41)	1	0.68 (0.49 - 0.93)	0.0006
I84 : Hemorrhoids	1.46 (1.05 - 2.04)	0.002	0.82 (0.70 - 0.96)	0.0002	1.28 (0.89 - 1.83)	1	0.81 (0.68 - 0.95)	0.0001
J00 : Acute nasopharyngitis [common cold]	1.4 (1.20 - 1.62)	<0.0001	1.02 (0.82 - 1.27)	1	1.3 (1.12 - 1.52)	<0.0001	0.97 (0.77 - 1.23)	1
J01 : Acute sinusitis	1.48 (1.20 - 1.82)	<0.0001	0.91 (0.78 - 1.07)	1	1.39 (1.11 - 1.72)	<0.0001	0.91 (0.77 - 1.08)	1
J02 : Acute pharyngitis	1.35 (1.14 - 1.59)	<0.0001	0.83 (0.71 - 0.96)	0.0004	1.32 (1.11 - 1.57)	<0.0001	0.81 (0.69 - 0.96)	0.0004
J04 : Acute laryngitis and tracheitis	1.36 (1.12 - 1.65)	<0.0001	0.94 (0.71 - 1.24)	1	1.3 (1.05 - 1.59)	0.0003	0.93 (0.69 - 1.25)	1
J11 : Influenza due to unidentified influenza virus	1.31 (1.08 - 1.60)	<0.0001	0.87 (0.70 - 1.09)	1	1.25 (1.02 - 1.54)	0.005	0.86 (0.68 - 1.09)	1
J20 : Acute bronchitis	1.46 (1.19 - 1.80)	<0.0001	0.84 (0.65 - 1.07)	1	1.41 (1.14 - 1.75)	<0.0001	0.74 (0.56 - 0.97)	0.003
J30 : Vasomotor and allergic rhinitis	1.42 (0.98 - 2.06)	0.048	0.7 (0.58 - 0.85)	<0.0001	1.39 (0.93 - 2.08)	0.288	0.72 (0.59 - 0.88)	<0.0001
J31 : Chronic rhinitis, nasopharyngitis and pharyngitis	1.44 (0.96 - 2.18)	0.123	0.94 (0.67 - 1.33)	1	1.3 (0.85 - 2.00)	1	0.75 (0.51 - 1.11)	0.97
J32 : Chronic sinusitis	1.45 (0.75 - 2.82)	1	0.77 (0.47 - 1.24)	1	1.25 (0.62 - 2.53)	1	*	*
J34 : Other and unspecified disorders of nose and nasal sinuses	1.11 (0.71 - 1.73)	1	0.81 (0.57 - 1.17)	1	1.08 (0.66 - 1.75)	1	0.81 (0.55 - 1.18)	1
J40 : Bronchitis, not specified as acute or chronic	1.51 (1.10 - 2.07)	0.0001	1.18 (0.75 - 1.85)	1	1.37 (0.96 - 1.96)	0.126	1.18 (0.75 - 1.85)	1
J45 : Asthma	1.38 (1.05 - 1.83)	0.001	0.81 (0.70 - 0.93)	<0.0001	1.28 (0.95 - 1.73)	0.266	0.83 (0.72 - 0.97)	0.0007
K04 : Diseases of pulp and periapical tissues	1.6 (0.91 - 2.80)	0.275	0.88 (0.61 - 1.28)	1	1.47 (0.79 - 2.76)	1	0.8 (0.54 - 1.20)	1
K12 : Stomatitis and related lesions	1.11 (0.56 - 2.18)	1	0.77 (0.51 - 1.14)	1	1.03 (0.50 - 2.12)	1	0.76 (0.50 - 1.17)	1
K21 : Gastro-esophageal reflux disease	1.26 (0.94 - 1.68)	0.48	0.74 (0.58 - 0.94)	0.0005	1.1 (0.80 - 1.52)	1	0.7 (0.53 - 0.92)	<0.0001
K29 : Gastritis and duodenitis	1.54 (1.11 - 2.12)	<0.0001	0.75 (0.55 - 1.02)	0.081	1.26 (0.88 - 1.79)	1	0.67 (0.47 - 0.95)	0.003
K30 : Functional dyspepsia	1.23 (0.68 - 2.23)	1	0.77 (0.63 - 0.95)	0.0005	0.9 (0.44 - 1.82)	1	0.72 (0.58 - 0.91)	<0.0001
K44 : Diaphragmatic hernia	1.42 (1.10 - 1.83)	<0.0001	0.67 (0.46 - 0.98)	0.011	1.31 (1.00 - 1.72)	0.027	0.67 (0.45 - 1.01)	0.042
K58 : Irritable bowel syndrome	1.43 (1.06 - 1.93)	0.0007	0.82 (0.66 - 1.01)	0.068	1.42 (1.04 - 1.94)	0.003	0.82 (0.65 - 1.03)	0.189
K59 : Functional intestinal disorders	1.9 (1.47 - 2.44)	<0.0001	1.58 (1.35 - 1.84)	<0.0001	1.66 (1.27 - 2.17)	<0.0001	1.5 (1.27 - 1.78)	<0.0001
K62 : Other diseases of anus and rectum	0.86 (0.68 - 1.10)	1	0.86 (0.68 - 1.10)	1	1.11 (0.53 - 2.33)	1	0.77 (0.58 - 1.01)	0.05
K80 : Cholelithiasis	1.35 (0.69 - 2.63)	1	0.81 (0.54 - 1.22)	1	1.33 (0.67 - 2.66)	1	0.74 (0.47 - 1.19)	1
L02 : Cutaneous abscess, furuncle and carbuncle	1.5 (0.93 - 2.40)	0.201	0.84 (0.65 - 1.09)	1	1.37 (0.80 - 2.34)	1	0.82 (0.62 - 1.09)	1
L03 : Cellulitis and acute lymphangitis	1.78 (0.99 - 3.20)	0.036	1.01 (0.83 - 1.23)	1	1.57 (0.82 - 3.03)	1	0.92 (0.74 - 1.15)	1
L21 : Seborrheic dermatitis	1.67 (0.81 - 3.45)	1	0.86 (0.63 - 1.19)	1	*	*	0.88 (0.63 - 1.24)	1
L29 : Pruritus	1.3 (0.91 - 1.85)	0.865	0.99 (0.78 - 1.25)	1	1.16 (0.79 - 1.71)	1	0.85 (0.65 - 1.11)	1
L30 : Other and unspecified dermatitis	1.43 (1.08 - 1.89)	0.0002	1.0 (0.84 - 1.18)	1	1.37 (1.01 - 1.87)	0.016	1.0 (0.84 - 1.20)	1
L40 : Psoriasis	1.97 (1.18 - 3.27)	<0.0001	0.92 (0.71 - 1.20)	1	1.44 (0.80 - 2.61)	1	0.91 (0.69 - 1.20)	1
L50 : Urticaria	1.83 (1.05 - 3.18)	0.006	0.83 (0.61 - 1.12)	1	1.84 (1.02 - 3.30)	0.014	0.71 (0.51 - 1.00)	0.031
L62 : Other nonscarring hair loss	1.84 (1.07 - 3.16)	0.003	0.68 (0.45 - 1.04)	0.089	1.92 (1.06 - 3.49)	0.006	0.72 (0.46 - 1.12)	0.871
L70 : Acne	1.86 (1.20 - 2.89)	<0.0001	0.79 (0.64 - 0.98)	0.006	1.72 (1.08 - 2.75)	0.002	0.77 (0.61 - 0.96)	0.001
L98 : Other disorders of skin and subcutaneous tissue, not elsewhere classified	1.38 (0.74 - 2.57)	1	0.75 (0.62 - 0.91)	<0.0001	1.45 (0.73 - 2.90)	1	0.7 (0.57 - 0.86)	<0.0001
M10 : Gout	1.11 (0.45 - 2.73)	1	0.53 (0.34 - 0.81)	<0.0001	*	*	0.53 (0.33 - 0.85)	<0.0001
M13 : Other arthritis	1.26 (0.65 - 2.43)	1	0.75 (0.52 - 1.10)	0.768	1.11 (0.52 - 2.33)	1	0.69 (0.45 - 1.04)	0.106
M19 : Other and unspecified osteoarthritis	1.2 (0.86 - 1.67)	1	0.73 (0.58 - 0.92)	<0.0001	1.02 (0.70 - 1.48)	1	0.68 (0.52 - 0.87)	<0.0001
M25 : Pain in joint	1.5 (1.21 - 1.86)	<0.0001	0.97 (0.85 - 1.11)	1	1.39 (1.10 - 1.75)	<0.0001	0.91 (0.79 - 1.05)	1
M47 : Spondylosis	1.51 (0.97 - 2.34)	0.067	1.2 (0.89 - 1.62)	1	1.24 (0.76 - 2.00)	1	1.09 (0.78 - 1.52)	1
M51 : Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders	1.48 (0.82 - 2.69)	1	1.13 (0.77 - 1.66)	1	1.23 (0.60 - 2.52)	1	1.0 (0.65 - 1.53)	1

M53 : Cervicobrachial syndrome	1.85 (1.32 - 2.57)	<0.0001	1.15 (0.77 - 1.73)	1	1.47 (1.01 - 2.16)	0.019	1.01 (0.65 - 1.57)	1
M54 : Dorsalgia	1.56 (1.35 - 1.80)	<0.0001	1.0 (0.90 - 1.10)	1	0.98 (0.62 - 1.61)	<0.0001	0.9 (0.81 - 1.01)	0.057
M62 : Contracture of muscle	2.09 (1.44 - 3.02)	<0.0001	0.89 (0.70 - 1.55)	1	*	*	*	*
M75 : Shoulder lesions	1.28 (0.98 - 1.68)	0.065	1.12	1	1.11 (0.82 - 1.51)	1	0.78 (0.60 - 1.03)	0.106
M77 : Other enthesopathies	1.38 (1.07 - 1.77)	0.0003	0.77 (0.62 - 0.96)	0.0009	1.11 (0.84 - 1.48)	1	0.74 (0.58 - 0.94)	0.0003
M79 : Pain in limb, foot / Myalgia	1.72 (1.40 - 2.11)	<0.0001	1.1 (1.00 - 1.22)	0.057	1.46 (1.16 - 1.83)	<0.0001	0.96 (0.86 - 1.07)	1
M81 : Osteoporosis without current pathological fracture	1.35 (0.73 - 2.48)	1	1.07 (0.74 - 1.53)	1	1.21 (0.61 - 2.39)	1	1.0 (0.67 - 1.49)	1
N30 : Cystitis	1.68 (1.34 - 2.12)	<0.0001	1.22 (1.07 - 1.39)	<0.0001	1.5 (1.16 - 1.94)	<0.0001	1.21 (1.05 - 1.39)	0.0001
N39 : Urinary tract infection, site not specified	1.79 (1.27 - 2.51)	<0.0001	1.47 (1.27 - 1.70)	<0.0001	1.68 (1.14 - 2.46)	<0.0001	1.38 (1.18 - 1.61)	<0.0001
N64 : Other disorders of breast	2.15 (1.24 - 3.74)	<0.0001	0.88 (0.70 - 1.11)	1	1.48 (0.78 - 2.79)	1	0.77 (0.60 - 1.00)	0.033
N76 : Other inflammation of vagina and vulva	1.57 (0.92 - 2.69)	0.233	0.86 (0.61 - 1.21)	1	1.38 (0.75 - 2.53)	1	0.83 (0.58 - 1.19)	1
N91 : Absent, scanty and rare menstruation	1.62 (0.99 - 2.63)	0.03	0.85 (0.65 - 1.10)	1	1.22 (0.70 - 2.13)	1	0.87 (0.66 - 1.15)	1
N92 : Excessive, frequent and irregular menstruation	1.7 (1.10 - 2.62)	0.0005	0.85 (0.73 - 0.98)	0.002	1.45 (0.91 - 2.33)	0.447	0.86 (0.73 - 1.00)	0.018
N94 : Pain and other conditions associated with female genital organs and menstrual cycle	1.54 (0.96 - 2.48)	0.084	0.99 (0.78 - 1.27)	1	1.56 (0.95 - 2.56)	0.113	0.99 (0.77 - 1.27)	1
N95 : Menopausal and other perimenopausal disorders	1.18 (0.82 - 1.70)	1	0.92 (0.77 - 1.09)	1	1.0 (0.66 - 1.51)	1	0.88 (0.73 - 1.07)	1
R05 : Cough	1.24 (1.04 - 1.47)	0.0005	1.04 (0.71 - 1.55)	1	1.2 (1.01 - 1.44)	0.014	0.96 (0.62 - 1.47)	1
R06 : Abnormalities of breathing	1.39 (0.90 - 2.15)	0.61	0.79 (0.56 - 1.11)	1	1.33 (0.82 - 2.17)	1	0.7 (0.48 - 1.02)	0.061
R07 : Pain in throat and chest	1.32 (0.97 - 1.81)	0.115	0.82 (0.63 - 1.08)	1	1.2 (0.84 - 1.70)	1	0.71 (0.52 - 0.96)	0.003
R10 : Abdominal and pelvic pain	1.28 (1.06 - 1.55)	0.0001	0.88 (0.74 - 1.05)	1	1.18 (0.97 - 1.45)	0.285	0.84 (0.70 - 1.01)	0.077
R20 : Paresthesia of skin	14.81 (9.74 - 22.52)	<0.0001	9.45 (7.42 - 12.04)	<0.0001	*	*	*	*
R21 : Rash and other nonspecific skin eruption	1.4 (0.80 - 2.45)	1	1.04 (0.82 - 1.31)	1	1.02 (0.51 - 2.05)	1	0.93 (0.72 - 1.20)	1
R25 : Abnormal involuntary movements	1.47 (0.89 - 2.45)	0.654	2.32 (1.80 - 2.99)	<0.0001	1.21 (0.66 - 2.19)	1	*	*
R42 : Dizziness and giddiness	2.57 (1.93 - 3.41)	<0.0001	2.08 (1.78 - 2.41)	<0.0001	*	*	*	*
R51 : Headache	1.48 (1.18 - 1.87)	<0.0001	1.28 (1.01 - 1.62)	0.019	1.17 (0.90 - 1.51)	1	1.14 (0.88 - 1.48)	1
R52 : Pain, unspecified	1.66 (1.26 - 2.18)	<0.0001	0.96 (0.67 - 1.39)	1	1.32 (0.96 - 1.82)	0.172	0.83 (0.55 - 1.25)	1
R53 : Malaise and fatigue	1.76 (1.47 - 2.10)	<0.0001	1.45 (1.13 - 1.87)	<0.0001	1.55 (1.28 - 1.88)	<0.0001	1.21 (0.92 - 1.59)	1
R55 : Syncope and collapse	2.01 (1.13 - 3.58)	0.0007	1.07 (0.74 - 1.55)	1	1.33 (0.70 - 2.54)	1	0.93 (0.62 - 1.41)	1
R59 : Enlarged lymph nodes	1.76 (1.12 - 2.78)	0.0004	0.86 (0.54 - 1.39)	1	1.68 (1.04 - 2.69)	0.006	*	*
R60 : Edema, not elsewhere classified	1.47 (0.88 - 2.47)	0.702	0.99 (0.68 - 1.44)	1	1.36 (0.75 - 2.44)	1	0.79 (0.51 - 1.22)	1
R63 : Abnormal weight loss or gain	1.7 (1.04 - 2.78)	0.007	1.03 (0.67 - 1.59)	1	1.55 (0.88 - 2.70)	0.502	0.81 (0.49 - 1.33)	1
S83 : Dislocation and sprain of joints and ligaments of knee	1.51 (0.81 - 2.80)	1	0.7 (0.44 - 1.12)	0.717	1.27 (0.63 - 2.54)	1	*	*
S93 : Dislocation and sprain of joints and ligaments at ankle, foot and toe level	1.69 (1.17 - 2.45)	<0.0001	1.06 (0.78 - 1.45)	1	1.41 (0.94 - 2.10)	0.204	0.97 (0.69 - 1.36)	1
T14 : Injury of unspecified body region	1.66 (1.34 - 2.05)	<0.0001	0.93 (0.76 - 1.14)	1	1.34 (1.06 - 1.69)	0.0003	0.87 (0.70 - 1.08)	1
T78 : Adverse effects, not elsewhere classified	1.28 (1.02 - 1.61)	0.005	0.92 (0.68 - 1.25)	1	1.24 (0.97 - 1.57)	0.149	0.92 (0.67 - 1.28)	1
Z01 : Encounter for other special examination without complaint, suspected or reported diagnosis	1.16 (0.71 - 1.91)	1	1.11 (0.70 - 1.74)	1	0.75 (0.39 - 1.44)	1	*	*
Z02 : Encounter for administrative examination	1.37 (1.13 - 1.65)	<0.0001	1.24 (1.04 - 1.48)	0.0009	1.2 (0.98 - 1.48)	0.106	1.03 (0.84 - 1.27)	1
Z13 : Encounter for screening for other diseases and disorders	1.04 (0.66 - 1.65)	1	0.65 (0.41 - 1.05)	0.128	1.04 (0.64 - 1.70)	1	*	*
Z30 : Encounter for contraceptive management	1.35 (1.08 - 1.68)	<0.0001	0.98 (0.89 - 1.09)	1	1.4 (1.11 - 1.76)	<0.0001	1.06 (0.96 - 1.18)	1
Z76 : Persons encountering health services	1.22 (0.99 - 1.50)	0.065	0.81 (0.59 - 1.11)	1	1.12 (0.89 - 1.40)	1	0.84 (0.59 - 1.20)	1



808

809

810 **eTable 6. ORs for all health conditions individually associated with a future diagnosis of MS for the five-year**  
811 **period leading up to the index date. In the primary analysis, we used the first recorded G35 code or**  
812 **demyelinating event as the index date, whereas, in the sensitivity analysis, we used the first recorded G35, or**  
813 **demyelinating event or first symptom suggestive of MS as the index date. . . \* cannot be calculated because the**  
814 **health condition is used to define the index date in the sensitivity analysis. . . \* cannot be calculated because too**  
815 **few presentations were recorded (health conditions defined by ICD-10 codes with a relative frequency of less**  
816 **than 0.5%). ORs and p-value are adjusted for multiple comparisons using the Bonferroni method. P-values**  
817 **greater to 1 are clipped to 1.**

	Primary analysis						Sensitivity analysis					
	FR			UK			FR			UK		
	No. (%) [MS:controls]	OR (Adjusted 95% CI)	Adjusted p value	No. (%) [MS:controls]	OR (Adjusted 95% CI)	Adjusted p value	No. (%) [MS:controls]	OR (Adjusted 95% CI)	Adjusted p value	No. (%) [MS:controls]	OR (Adjusted 95% CI)	Adjusted p value
F32 : Major depressive disorder, single episode	789 (18.1): 1350 (10.8)	1.84 (1.52 - 2.21)	<0.0001	3801 (24.0): 8297 (19.6)	1.24 (1.14 - 1.36)	<0.0001	630 (14.4): 1139 (9.1)	1.62 (1.32 - 1.98)	<0.0001	3295 (20.8): 7030 (16.6)	1.22 (1.11 - 1.34)	<0.0001
F52 : Sexual dysfunction	154 (3.6): 246 (2.0)	1.92 (1.29 - 2.86)	<0.0001	388 (2.5): 650 (1.5)	1.54 (1.19 - 1.99)	<0.0001	123 (2.8): 209 (1.7)	1.69 (1.10 - 2.62)	0.0008	305 (1.9): 515 (1.2)	1.47 (1.11 - 1.95)	<0.0001
G40 : Epilepsy and recurrent seizures	61 (1.4): 71 (0.6)	2.54 (1.30 - 4.97)	<0.0001	188 (1.2): 363 (0.9)	1.43 (1.00 - 2.04)	0.021	..*	..*	..*	167 (1.1): 308 (0.7)	1.46 (1.00 - 2.12)	0.022
H81 : Disorders of vestibular function	144 (3.3): 184 (1.5)	2.22 (1.44 - 3.43)	<0.0001	330 (2.1): 557 (1.3)	1.49 (1.13 - 1.97)	<0.0001	* *	* *	*	* *	*	*
K59 : Functional intestinal disorders	406 (9.3): 655 (5.2)	1.9 (1.47 - 2.44)	<0.0001	1171 (7.4): 1845 (4.4)	1.58 (1.35 - 1.84)	<0.0001	340 (7.8): 591 (4.7)	1.66 (1.27 - 2.17)	<0.0001	904 (5.7): 1427 (3.4)	1.5 (1.27 - 1.78)	<0.0001
N30 : Cystitis	478 (11.0): 855 (6.8)	1.68 (1.34 - 2.12)	<0.0001	1422 (9.0): 2951 (7.0)	1.22 (1.07 - 1.39)	<0.0001	367 (8.4): 687 (5.5)	1.5 (1.16 - 1.94)	<0.0001	1176 (7.4): 2385 (5.6)	1.21 (1.05 - 1.39)	0.0001
N39 : Urinary tract infection, site not specified	217 (5.0): 348 (2.8)	1.79 (1.27 - 2.51)	<0.0001	1218 (7.7): 2263 (5.4)	1.47 (1.27 - 1.70)	<0.0001	165 (3.8): 268 (2.1)	1.68 (1.14 - 2.46)	<0.0001	997 (6.3): 1904 (4.5)	1.38 (1.18 - 1.61)	<0.0001
R20 : Paresthesia of skin	512 (11.7): 103 (0.8)	14.81 (9.74 - 22.52)	<0.0001	1220 (7.7): 363 (0.9)	9.45 (7.42 - 12.04)	<0.0001	* *	* *	*	* *	*	*
R42 : Dizziness and giddiness	372 (8.5): 415 (3.3)	2.57 (1.93 - 3.41)	<0.0001	1300 (8.2): 1667 (4.0)	2.08 (1.78 - 2.41)	<0.0001	* *	* *	*	* *	*	*
R51 : Headache	464 (10.6): 908 (7.2)	1.48 (1.18 - 1.87)	<0.0001	403 (2.6): 844 (2.0)	1.28 (1.00 - 1.62)	0.019	333 (7.6): 776 (6.2)	1.17 (0.90 - 1.51)	1	324 (2.0): 730 (1.7)	1.14 (0.88 - 1.48)	1
R53 : Malaise and fatigue	891 (20.4): 1574 (12.5)	1.76 (1.47 - 2.10)	<0.0001	376 (2.4): 692 (1.6)	1.45 (1.13 - 1.87)	<0.0001	703 (16.1): 1301 (10.4)	1.55 (1.28 - 1.88)	<0.0001	294 (1.9): 633 (1.5)	1.21 (0.92 - 1.59)	1

818

819

820 **eTable 7. Pooled, UK, and French ORs for all health problems individually associated with MS in the**  
821 **sensitivity analysis during the five years before the occurrence of the first symptoms. We used the whole**  
822 **sensitivity cohort and excluded patients with less than 5 years of history before the index date in the database.**  
823 **\* for ORs associated with corrected p-values below 0.05 or initial p-values below 0.05/113. ORs and p-value are**  
824 **adjusted for multiple comparisons using the Bonferroni method.**

	Pooled cohort (No. MS : 14932 No. no MS : 25193)		UK cohort (No. MS : 12412 No. no MS : 21736)		French cohort (No. MS : 2520 No. no MS : 3457)	
	No. (%) [MS : no MS]	OR (adjusted 95% CI)	No. (%) [MS : no MS]	OR (adjusted 95% CI)	No. (%) [MS : no MS]	OR (adjusted 95% CI)
F32 : Major depressive disorder, single episode	2956 (19.80) : 3902 (15.49)	1.30 (1.20 - 1.40)*	2574 (20.74) : 3554 (16.35)	1.29 (1.14 - 1.45)*	382 (15.16) : 349 (10.10)	1.57 (1.17 - 2.11)*
F52 : Sexual dysfunction	310 (2.08) : 343 (1.36)	1.50 (1.20 - 1.87)*	241 (1.94) : 285 (1.31)	1.43 (1.03 - 1.99)*	70 (2.78) : 59 (1.71)	1.67 (0.86 - 3.22)
K59 : Constipation	918 (6.15) : 948 (3.76)	1.59 (1.39 - 1.82)*	712 (5.74) : 767 (3.53)	1.55 (1.23 - 1.94)*	206 (8.17) : 180 (5.21)	1.62 (1.10 - 2.40)*
N30 : Cystitis	1135 (7.60) : 1517 (6.02)	1.23 (1.10 - 1.38)*	923 (7.44) : 1298 (5.97)	1.20 (1.01 - 1.43)*	212 (8.41) : 218 (6.31)	1.34 (0.92 - 1.94)
N39 : Urinary tract infection, site not specified	876 (5.87) : 1091 (4.33)	1.36 (1.19 - 1.55)*	779 (6.28) : 991 (4.56)	1.38 (1.14 - 1.66)*	97 (3.85) : 99 (2.86)	1.32 (0.77 - 2.26)

825  
826

827  
828

**eTable 8. Characteristics of patients with MS and individuals without MS with at least five years of data before the index date in the two cohorts. The data are shown as percentages or medians (IQR).**

	Size, n	Sex (female)	Age at first symptom of MS	Person-years of data available before diagnosis	Number of visits per year before diagnosis
<b><i>Pooled</i></b>					
MS	14932	70.7%	44 (34 - 55)	8.4 (5.8 - 12.3)	4.6 (1.3 - 5.5)
No MS	25193	70.2%	46 (37 - 56)	8.5 (5.9 - 12.4)	3.8 (1.1 - 5.0)
<b><i>UK</i></b>					
MS	12412	70.7%	45 (35 - 55)	8.6 (6.0 - 12.6)	4.6 (1.3 - 5.6)
No MS	21736	70.2%	46 (36 - 56)	8.7 (6.1 - 12.7)	4.0 (1.2 - 5.2)
<b><i>France</i></b>					
MS	2520	70.7%	41 (32 - 51)	7.2 (5.1 - 10.2)	4.3 (1.3 - 5.0)
No MS	3457	70.5%	42 (33 - 53)	7.3 (5.3 - 10.3)	2.9 (0.7 - 3.9)

829  
830

831  
832  
833

**eTable 9. Characteristics of patients with MS and individuals without MS with at least two years of data before and after the index date in the two cohorts. The data are shown as percentages or medians (IQR).**

	Sex								Age at onset						Year of diagnosis			
	Whole cohort		Women		Men		<40		[40,53]		>53		<2010		[2010,2017]		>2017	
	MS	No MS	MS	no MS	MS	no MS	MS	no MS	MS	no MS	MS	no MS	MS	no MS	MS	no MS	MS	no MS
<b>Pooled</b>																		
Size, n	15454	26253	10966	18821	4488	7442	5151	7079	5152	9620	5151	9253	10283	18964	4417	6419	754	732
Sex (female)	71.3%	72.0%	100%	100%	0%	0%	73.9%	74.6%	71.8%	73.2%	68.6%	69.1%	71.8%	72.3%	69.9%	70.9%	73.1%	74.4%
Age at index date	44 (35 - 54)	45 (37 - 54)	44 (34 - 54)	45 (36 - 54)	46 (36 - 55)	46 (37 - 56)	31 (26 - 35)	31 (26 - 35)	44 (41 - 48)	44 (41 - 48)	59 (54 - 66)	60 (56 - 67)	46 (36 - 56)	46 (37 - 56)	41 (32 - 51)	43 (37 - 55)	40 (31 - 51)	41 (33 - 52)
Person-years of data available before diagnosis	6.3 (3.5 - 10.2)	6.3 (3.6 - 9.9)	6.3 (3.5 - 10.2)	6.3 (3.6 - 9.9)	6.3 (3.4 - 10.1)	6.3 (3.6 - 9.8)	5.8 (3.2 - 9.8)	5.3 (3.1 - 8.8)	6.3 (3.6 - 10.0)	6.2 (3.6 - 9.7)	6.7 (3.6 - 10.5)	6.9 (4.0 - 10.7)	5.7 (3.3 - 8.6)	5.9 (3.5 - 8.8)	8.4 (3.9 - 13.8)	8.2 (4.2 - 13.7)	9.9 (4.5 - 16.6)	8.1 (3.7 - 16.9)
Number of visits per year before diagnosis	5.3 (1.5 - 6.3)	4.1 (1.3 - 5.4)	5.5 (1.6 - 6.5)	4.4 (1.4 - 5.8)	4.7 (1.1 - 5.3)	3.5 (1.0 - 4.5)	4.6 (1.4 - 5.5)	3.7 (1.2 - 4.8)	5.1 (1.3 - 5.8)	3.7 (1.2 - 4.8)	6.2 (1.7 - 7.8)	4.9 (1.5 - 6.5)	5.3 (1.3 - 6.4)	4.0 (1.2 - 5.3)	5.2 (1.7 - 6.0)	4.3 (1.5 - 5.7)	5.2 (1.7 - 5.5)	4.9 (1.9 - 6.0)
<b>UK</b>																		
Size, n	12565	22751	8964	16396	3601	6365	4076	5993	4279	8318	4299	8189	8848	17087	3207	5106	510	544
Sex (female)	71.3%	72.0%	100%	100%	0%	0%	73.9%	74.6%	71.8%	73.2%	68.6%	69.1%	71.8%	72.3%	69.9%	70.9%	73.1%	74.4%
Age at index date	45 (35 - 55)	46 (37 - 55)	44 (35 - 54)	46 (36 - 55)	46 (36 - 56)	47 (38 - 56)	31 (26 - 35)	31 (26 - 35)	44 (41 - 48)	44 (41 - 48)	59 (55 - 66)	60 (56 - 67)	46 (37 - 56)	49 (40 - 58)	41 (32 - 51)	43 (34 - 52)	40 (30 - 51)	41 (33 - 52)
Person-years of data available before diagnosis	6.8 (3.9 - 10.8)	6.6 (3.8 - 10.4)	6.8 (3.9 - 10.9)	6.6 (3.8 - 10.4)	6.8 (3.9 - 10.6)	6.6 (3.8 - 10.3)	6.3 (3.5 - 10.6)	5.6 (3.2 - 9.2)	6.8 (4.1 - 10.5)	6.5 (3.8 - 10.2)	7.3 (4.2 - 11.0)	7.2 (4.3 - 11.1)	6.1 (3.8 - 9.1)	6.1 (3.6 - 9.2)	9.9 (4.8 - 15.5)	9.2 (4.6 - 14.7)	12.3 (5.7 - 18.6)	10.2 (4.4 - 17.8)
Number of visits per year before diagnosis	5.3 (1.4 - 6.3)	4.2 (1.2 - 5.5)	5.5 (1.6 - 6.6)	4.4 (1.4 - 5.8)	4.8 (1.1 - 5.3)	3.4 (0.9 - 4.4)	4.6 (1.4 - 5.5)	3.8 (1.2 - 4.9)	5.0 (1.2 - 5.8)	3.7 (1.1 - 4.8)	6.2 (1.7 - 7.9)	4.9 (1.4 - 6.6)	5.2 (1.3 - 6.3)	4.0 (1.1 - 5.3)	5.5 (1.7 - 6.4)	4.5 (1.6 - 6.0)	5.6 (1.7 - 6.0)	5.2 (1.9 - 6.3)
<b>FR</b>																		
Size, n	2889	3502	2002	2425	887	1077	1075	1086	873	1302	852	1064	1435	1877	1210	1313	244	189
Sex (female)	69.3%	69.2%	100%	100%	0%	0%	71.1%	70.9%	72.1%	71.9%	63.2%	63.8%	69.4%	68.4%	68.8%	69.8%	71.7%	73.5%
Age at index date	42 (33 - 52)	44 (34 - 54)	42 (33 - 51)	44 (35 - 53)	44 (34 - 55)	45 (35 - 55)	30 (24 - 32)	31 (24 - 36)	44 (41 - 48)	45 (41 - 49)	58 (54 - 66)	59 (55 - 67)	43 (34 - 55)	45 (35 - 5)	41 (32 - 50)	41 (33 - 50)	41 (31 - 51)	43 (51 - 52)
Person-years of data available before diagnosis	5.6 (3.3 - 9.2)	4.9 (3.2 - 7.6)	5.6 (3.3 - 8.9)	4.9 (3.2 - 7.6)	5.7 (3.1 - 9.6)	4.9 (3.2 - 7.6)	5.3 (3.4 - 8.7)	4.4 (3.0 - 6.8)	6.2 (3.6 - 9.7)	5.0 (3.3 - 7.7)	5.8 (3.6 - 9.2)	4.9 (3.1 - 7.6)	4.0 (2.7 - 6.0)	3.2 (2.3 - 5.1)	5.5 (2.8 - 9.4)	5.4 (3.4 - 8.8)	6.7 (3.3 - 11.9)	4.5 (2.6 - 8.8)
Number of visits per year before diagnosis	4.9 (2.1 - 6.4)	3.8 (1.5 - 5.0)	5.0 (2.2 - 6.5)	4.0 (1.6 - 5.2)	4.7 (1.8 - 5.9)	3.5 (1.5 - 4.6)	4.0 (2.0 - 5.1)	3.1 (1.4 - 4.0)	4.8 (1.9 - 6.3)	3.8 (1.5 - 4.7)	5.9 (1.9 - 7.6)	4.9 (1.9 - 6.2)	6.1 (1.9 - 7.0)	4.1 (1.5 - 5.3)	4.3 (1.5 - 5.2)	3.5 (1.3 - 4.6)	4.5 (1.6 - 4.7)	3.9 (1.8 - 4.6)

834  
835

836 **eTable 10. ORs in the UK cohort for all health conditions individually associated with MS in the sensitivity**  
 837 **analysis during the five years before and five years after the occurrence of the first symptoms. Individuals**  
 838 **with MS are compared with controls without MS. We used the whole sensitivity cohort, sex-based cohorts, age-**  
 839 **at-onset cohorts, and year-at-diagnosis cohorts. . \* cannot be calculated because too few presentations were**  
 840 **recorded. \* for ORs associated with corrected p-values below 0.05 or initial p-value below 0.05/5. p-value are**  
 841 **adjusted for multiple comparisons using the Bonferroni method.**

842

	Whole cohort (MS : 12565 Control : 22751)	Sex		Age at onset			Year of diagnosis		
		Women (MS : 8964 Control : 16396)	Men (No. MS : 3601 Control : 6365)	<40 (No. MS : 4076 Control : 5993)	[40,53] (No. MS : 4279 Control : 8318)	>53 (No. MS : 4299 Control : 8189)	<2010 (No. MS : 8848 Control : 17087)	[2010,2017] (No. MS : 3207 Control : 5106)	>2017 (No. MS : 510 Control : 544)
<b>Before diagnosis</b>									
F32 : Major depressive disorder, single episode	1.36 (1.22 - 1.52)*	1.34 (1.18 - 1.51)*	1.49 (1.18 - 1.88)*	1.34 (1.09 - 1.64)*	1.39 (1.17 - 1.65)*	1.33 (1.10 - 1.61)*	1.39 (1.22 - 1.58)*	1.31 (1.07 - 1.62)*	1.02 (0.60 - 1.72)
F52 : Sexual dysfunction	1.65 (1.18 - 2.31)*	1.08 (0.45 - 2.60)	1.75 (1.21 - 2.54)*	1.58 (0.65 - 3.84)	1.95 (1.12 - 3.39)*	1.53 (0.94 - 2.49)	1.67 (1.10 - 2.52)*	1.61 (0.88 - 2.94)	.*
K59 : Constipation	1.87 (1.50 - 2.35)*	1.69 (1.31 - 2.18)*	2.70 (1.65 - 4.43)*	1.35 (0.85 - 2.13)	1.86 (1.23 - 2.80)*	2.30 (1.65 - 3.21)*	2.11 (1.53 - 2.91)*	1.66 (1.18 - 2.35)*	1.15 (0.53 - 2.49)
N30 : Cystitis	1.36 (1.14 - 1.63)*	1.30 (1.08 - 1.57)	2.49 (1.33 - 4.69)*	1.14 (0.82 - 1.59)	1.19 (0.87 - 1.62)	1.73 (1.30 - 2.31)*	1.44 (1.15 - 1.79)*	1.22 (0.88 - 1.68)	1.09 (0.51 - 2.34)
N39 : Urinary tract infection, site not specified	1.41 (1.18 - 1.69)*	1.31 (1.08 - 1.60)	2.27 (1.36 - 3.80)*	1.16 (0.81 - 1.64)	1.32 (0.96 - 1.81)	1.70 (1.28 - 2.26)*	1.51 (1.23 - 1.86)*	1.10 (0.74 - 1.64)	1.53 (0.46 - 5.05)
<b>After diagnosis</b>									
F32 : Major depressive disorder, single episode	2.0 (1.85 - 2.16)*	1.84 (1.69 - 2.02)*	2.54 (2.17 - 2.98)*	2.17 (1.91 - 2.47)*	2.05 (1.79 - 2.34)*	1.91 (1.65 - 2.22)*	1.96 (1.79 - 2.14)*	2.11 (1.79 - 2.48)*	2.11 (1.21 - 3.68)*
F52 : Sexual dysfunction	3.03 (2.56 - 3.59)*	1.62 (1.04 - 2.53)*	3.35 (2.78 - 4.03)*	5.57 (3.85 - 8.05)*	4.3 (3.20 - 5.78)*	1.45 (1.09 - 1.92)*	3.17 (2.61 - 3.86)*	2.74 (1.93 - 3.89)*	.*
K59 : Constipation	3.56 (3.22 - 3.92)*	3.2 (2.86 - 3.59)*	4.83 (3.95 - 5.90)*	3.27 (2.70 - 3.98)*	4.57 (3.83 - 5.45)*	3.34 (2.87 - 3.88)*	3.77 (3.34 - 4.25)*	3.07 (2.57 - 3.67)*	2.54 (1.47 - 4.39)*
N30 : Cystitis	2.66 (2.42 - 2.92)*	2.36 (2.13 - 2.61)*	5.9 (4.43 - 7.86)*	2.33 (1.95 - 2.79)*	2.88 (2.45 - 3.38)*	2.86 (2.46 - 3.34)*	2.76 (2.46 - 3.09)*	2.34 (1.95 - 2.81)*	2.21 (1.34 - 3.64)*
N39 : Urinary tract infection, site not specified	2.81 (2.53 - 3.13)*	2.57 (2.29 - 2.89)*	4.33 (3.30 - 5.70)*	2.35 (1.92 - 2.88)*	3.0 (2.48 - 3.63)*	3.02 (2.55 - 3.57)*	2.86 (2.54 - 3.22)*	2.74 (2.11 - 3.56)*	2.53 (1.08 - 5.91)*


843

844  
845  
846  
847  
848  
849  
850

**eTable 11. ORs in the French cohort for all health conditions individually associated with MS in the sensitivity analysis during the five years before and five years after the occurrence of the first symptoms. Individuals with MS are compared with controls without MS. We used the whole sensitivity cohort, sex-based cohorts, age-at-onset cohorts, and year-at-diagnosis cohorts. \* cannot be calculated because too few presentations were recorded. \* for ORs associated with corrected p-values below 0.05 or initial p-value below 0.05/5. p-value are adjusted for multiple comparisons using the Bonferroni method.**

	Whole cohort (MS : 2889 Control : 3502)	Sex		Age at onset			Year of diagnosis		
		Women (MS : 2002 Control : 2425)	Men (No. MS : 887 No. Control : 1077)	<40 (No. MS : 1075 No. Control : 1086)	[40,53] (No. MS : 873 No. Control : 1302)	>53 (No. MS : 852 No. Control : 1064)	<2010 (No. MS : 1435 No. Control : 1877)	[2010,2017] (No. MS : 1210 No. Control : 1313)	>2017 (No. MS : 244 No. Control : 189)
<b>Before diagnosis</b>									
F32 : Major depressive disorder, single episode	1.31 (1.07 - 1.62)*	1.26 (0.99 - 1.60)	1.50 (0.97 - 2.32)	1.86 (1.20 - 2.86)*	1.23 (0.90 - 1.70)	1.23 (0.84 - 1.78)	1.46 (1.11 - 1.93)*	1.31 (0.93 - 1.86)	0.86 (0.35 - 2.10)
F52 : Sexual dysfunction	1.26 (0.82 - 1.92)	1.43 (0.83 - 2.46)	1.01 (0.50 - 2.02)	1.89 (0.74 - 4.85)	1.41 (0.75 - 2.64)	0.85 (0.38 - 1.88)	1.36 (0.80 - 2.43)	1.39 (0.65 - 2.97)	.*
K59 : Constipation	1.48 (1.12 - 1.94)*	1.39 (1.01 - 1.91)*	1.78 (1.01 - 3.14)*	1.32 (0.82 - 2.13)	1.84 (1.12 - 3.00)*	1.36 (0.84 - 2.19)	1.44 (1.00 - 2.06)*	1.76 (1.08 - 2.89)*	1.39 (0.46 - 4.25)
N30 : Cystitis	1.24 (0.96 - 1.61)*	1.12 (0.85 - 1.48)	3.21 (1.35 - 7.62) *	1.12 (0.71 - 1.76)	1.24 (0.80 - 1.92)	1.42 (0.89 - 2.26)	1.44 (1.00 - 2.06)*	1.05 (0.68 - 1.60)	1.39 (0.57 - 3.39)
N39 : Urinary tract infection, site not specified	1.38 (0.92 - 2.07)	1.33 (0.86 - 2.06)	1.78 (0.62 - 5.14)	1.41 (0.68 - 2.92)	1.17 (0.59 - 2.35)	1.58 (0.79 - 3.15)	1.36 (0.94 - 1.95)	1.09 (0.59 - 2.00)	0.80 (0.23 - 2.81)
<b>After diagnosis</b>									
F32 : Major depressive disorder, single episode	1.85 (1.52 - 2.24)*	1.82 (1.46 - 2.27)*	1.93 (1.27 - 2.92)*	2.02 (1.43 - 2.85)*	1.64 (1.21 - 2.23)*	1.98 (1.32 - 2.98)*	1.96 (1.52 - 2.52)*	1.85 (1.32 - 2.60)*	1.06 (0.51 - 2.24)
F52 : Sexual dysfunction	1.99 (1.37 - 2.87)*	1.78 (1.08 - 2.94)*	2.26 (1.30 - 3.93)*	2.06 (1.00 - 4.27)*	2.54 (1.41 - 4.58)*	1.33 (0.69 - 2.56)	1.75 (1.12 - 2.75)*	2.12 (1.07 - 4.22)*	.*
K59 : Constipation	2.35 (1.83 - 3.00)*	2.37 (1.77 - 3.17)*	2.26 (1.43 - 3.57)*	2.62 (1.61 - 4.29)*	2.15 (1.43 - 3.23)*	2.2 (1.46 - 3.33)*	2.24 (1.61 - 3.11)*	2.27 (1.52 - 3.38)*	3.57 (1.14 - 11.18)*
N30 : Cystitis	1.69 (1.36 - 2.11)*	1.46 (1.16 - 1.83)*	.*	1.35 (0.94 - 1.92)	1.44 (0.99 - 2.10)	2.76 (1.79 - 4.26)*	1.92 (1.44 - 2.55)*	1.43 (0.99 - 2.08)	1.31 (0.50 - 3.48)
N39 : Urinary tract infection, site not specified	2.24 (1.66 - 3.01)*	2.24 (1.63 - 3.10)*	2.15 (0.99 - 4.68)	2.31 (1.30 - 4.07)*	1.77 (1.08 - 2.92)*	2.73 (1.65 - 4.53)*	2.36 (1.57 - 3.55)*	1.83 (1.17 - 2.88)*	.*

851  
852  
853  
854  
855  
856



857

858 **eFigure 3. ORs for significant associations in the sensitivity analysis for five years before the index date in**  
 859 **comparison to other auto-immune diseases.** Patients with MS are compared to patients with lupus and Crohn's  
 860 disease both in the French and UK cohorts. The size of the dot is proportional to the period prevalence. OR > 1  
 861 indicates a higher association in MS cohort compared to Crohn or lupus cohort. The period prevalence is defined  
 862 as the number of diagnoses or symptoms observed over the period divided by the number of patients at risk  
 863 during the period.

864

865


866

867

868




869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900




**eFigure 9. Period prevalence (%) of prescriptions associated with depression (A), urinary tract infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the physician per year (E) in the UK cohort. For a given prescription, the period prevalence is defined as the number of prescriptions observed over the period divided by the number of patients at risk during the period.**

901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948



**ion (A), urinary tract infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the physician per year (E) in the French cohort. For a given prescription, the period prevalence is defined as the number of prescriptions observed over the period divided by the number of patients at risk during the period.**


949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969



970 **eFigure 6. Period prevalence (%) of prescriptions associated with depression (A), urinary tract infections (B),**  
 971 **bacterial infections (C), and constipation (D), and mean number of visits to the physician per year (E) in the**  
 972 **pooled cohort, 15 years before diagnosis. Data are from the pooled cohort with individuals having data for the**  
 973 **entire 15 years before diagnosis time-window. For a given prescription, the period prevalence is defined as the**  
 974 **number of prescriptions observed over the period divided by the number of patients at risk during the period.**  
 975 **No. MS : 2726 (women: 1976), No. no MS : 2082 (W: 1488), No. Crohn's disease : 4849 (W: 2660), No. Lupus :**  
 976 **1040 (W: 903)**

977  
 978  
 979  
 980  
 981

982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998



**eFigure 7. Period prevalence (%) of prescriptions associated with depression (A), urinary tract infections (B), bacterial infections (C), and constipation (D), and mean number of visits to the physician per year (E) in the pooled cohort, 5 years before diagnosis up to 10 years after diagnosis. Data are from the pooled cohort with individuals having data for the entire 5 years before diagnosis to 10 years after diagnosis time-window. For a given prescription, the period prevalence is defined as the number of prescriptions observed over the period divided by the number of patients at risk during the period. No. MS : 3531 (women: 2581), No. no MS : 2060 (W: 1579), No. Crohn's disease : 4934 (W: 2814), No. Lupus : 1380 (W:1246)**

1006  
 1007  
 1008  
 1009